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SUMMARY 
                   Statins have been widely used clinically to reduce cholesterol level and exert 
therapeutic and preventative effects on high risk cardiovascular disorder patients. Recent 
research also showed that statins are beneficial factors not only as anticancer agents but 
also as preventative agents on some neurological diseases such as Stroke, Alzheimer 
Disease, and Multiple Sclerosis. To date, there is no report about the effects of statins on 
central dopaminergic systems and their related neurological diseases such as Parkinson’s 
disease. This work is mainly to explore the effects of simvastatin on central dopaminergic 
systems and its possible mechanism of action 
                 Since statins include two subtypes: lipophilic and hydrophilic. First we choose 
pravastatin and simvastatin (at dosage of 1.0mg/kg/day, 10mg/kg/day and 30mg/kg/day), 
which represent these two different types respectively, to test if both of them affect the 
central dopaminergic system to the same extent. Our data showed that only simvastatin 
treatment (10mg/kg/day and 30mg/kg/day) up-regulated D1 and D2 receptors in the 
prefrontal cortex, but no change in the striatum. However, pravastatin treatment did not 
cause any change in D1 and D2 receptor expression both in the prefrontal cortex and in 
the striatum. Since only the lipophilic simvastatin crosses the brain-blood-barrier (BBB) 
readily, the results implicated that simvastatin up-regulates dopamine receptors through a 
central mechanism(s) but not a peripheral one.  
                    In contrast, both pravastatin and simvastatin reduced the serum triglyceride 
but not the cholesterol level in SD rat, indicating that the effect on dopamine receptor 
expression is probably independent of changes in triglyceride level.  
Summary  xii
                   In order to verify that dopamine receptor function increased with up-
regulation of receptor expression, the effects of D1 and D2 activation on cAMP levels 
were studied in cortical synaptosome using immunoassay method. D1 receptor activation 
by chloro-APB (5μM) increased cAMP levels in synaptosomes prepared from the 
prefrontal cortex of control and simvastatin-treated rats by 88 and 285%, respectively. 
This effect was markedly attenuated by the selective D1 antagonist SCH-23390 (25μM). 
D2 receptor activation by quinpirole (5μM) had no effect on the basal cAMP levels in 
synaptosomes prepared from the prefrontal cortex of control and simvastatin-treated rats, 
while the same concentration of quinpirole completely abolished the D1 receptor-
mediated increase.  
                  Concurrent with the up-regulation of dopamine receptor D1 and D2 in the 
prefrontal cortex, eNOS was found to increase after simvastatin treatment in the 
prefrontal cortex, but not in the striatum. No changes in nNOS and iNOS were observed 
in both the prefrontal cortex and striatum. However, simvastatin was also shown to up-
regulate dopamine receptor D1 and D2 in the prefrontal cortex of eNOS knockout mice. 
Meanwhile, D1 and D2 receptors antagonists, SCH-23390 hydrochloride and haloperidol 
have not been found to affect the simvastatin-induced up-regulation of dopamine 
receptors. These results strongly indicated that up-regulation of the dopamine receptors 
after simvastatin treatment occurs independently of the up-regulation of eNOS.  
                 In vitro studies showed that dopamine content decreased in the prefrontal 
cortex but increased in the striatum while DA re-uptake in these brain regions remained 
unchanged.                                                                            
Summary  xiii
                     SD rats with unilateral lesion of the medial forebrain bundle by 6-
hydroxydopamine showed marked decrease in the expression of dopamine D1 and D2 
receptors in the prefrontal cortex. Simvastatin treatment (10 mg/kg/day for 4 weeks) 
restored receptor expression to control levels. Therefore, these observations suggest that 
simvastatin may have an effect on cognitive deficits associated with the loss of 
dopaminergic receptor function in advanced PD. 
                    In short, chronic treatment with simvastatin for 4 weeks significantly altered 
the dopaminergic systems in the prefrontal cortex of SD rats. The up-regulation of 
dopamine receptors expression with concurrent increase in receptor function may have 
specific implication on cognitive deficits in advanced Parkinson’s disease.  
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CHAPTER 1: INTRODUCTION 
               
 
               3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, or statins, have  
been widely used in clinical work as one main treatment for most forms of 
hypercholesterolemia because of their high efficacy and tolerability than other lipid-
lowering agents. In some basic research, it was found that statins reduced the infarct 
volume and area of the brain in stroke mice by up-regulating the endothelial nitric oxide 
synthase (eNOS) leading to increased blood flow and deceased neurological loss. It has 
also been showed that nitric oxide (NO) may interact with dopamine receptors by some 
unknown mechanisms. All of these create one challenging avenue of research for us that 
statins are probably intrinsically correlated to dopamine receptors and dopamine content.                    
This chapter aims to give an overview of the relationship between simvastatin and central 
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1.1 3-Hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors, or statins’ 
properties and their subtypes.  
1.1.1. Cholesterol biosynthesis and the inhibition mechanism of statins.  
The statins are drugs effective in reducing the serum cholesterol levels. 
Hence, medical treatment of hypercholesterolemia has received a major boost from the 
development of the statins, which inhibit 3-hydroxy-3-methylglutaryl- coenzyme A 
(HMG-CoA) reductase, a key enzyme in cholesterol biosynthesis. The biosynthetic 
pathway of cholesterol is detailed in Figure 1.1   
As the rate-limiting enzyme, HMG-CoA reductase is the most important and 
rational target for pharmacological intervention (Goldstein et al 1990; Chorvat et al 
1985). Statins act as the competitive inhibitors of HMG-CoA reductase by binding to 
the active site of this enzyme, thus preventing HMG-CoA reductase from binding with 
its substrate--HMG-CoA (Sit et al 1990).  
HMG-CoA reductase is regulated by a receptor system for low density 
lipoprotein (LDL) in human and other mammals (Brown et al. 1986). Its inhibition 
results in a dramatic reduction of circulating total and LDL cholesterol levels (Hoeg et 
al.1987). All statins produce compensatory increases in hepatic low-density lipoprotein 
receptors, resulting in an increased uptake of low-density lipoprotein cholesterol from 
the blood and the subsequent lowering of circulating cholesterol levels. Generally 
speaking, the clinical effects of statins appear not to differ to a significant extent (Sirtori 
et al., 1990), and their physicochemical characteristics may modulate their activities 
and potential toxicity. 
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1.1.2   Several types of statins and their properties.  
                   Examples of statins that are in clinical use include: fluvastatin, pravastatin, 
atorvastatin, cerivastatin, lovastatin, mevastatin, and simvastatin. Their chemical 
structures are described in Figure 1.2.  
                   They can be divided into two groups: hydrophilic and lipophilic. The 
hydrophilic agents include pravastatin and fluvastatin while the lipophilic agents include 
atorvastatin, cerivastatin, lovastatin, and simvastatin. Distribution into the central nervous 
system (CNS) is dependent on lipophilicity and affinity to p-glycoproteins, which 
constitute an important efflux mechanism for lipophilic drugs as part of the blood-brain 
barrier (BBB). For example, by determining the octanol-water partition coefficients 
(Po/w), Serajuddin et al (1991) showed that lipophilicity increases in the order 
pravastatin<mevastatin<lovastatin<simvasatain. Various pharmacokinetic properties of 
the drugs are listed in Table 1.1.  
                 
 
1.1.3 Statins and brain diseases  
                  In addition to the LDL cholesterol-lowing ability and beneficial effects on 
cardiovascular diseases, statins have been found to exert beneficial effects on brain 
diseases such as multiple sclerosis, Alzheimer’s disease, and stroke.  
                  Recent epidemiological studies showed that statins might produce a strong 
reduction in the incidence of Alzheimer’s disease (AD) (Zamrini et al.2004). Meanwhile, 
increasing interest in cholesterol-lowering drugs has been prompted by recent studies 
reporting that statins may provide protection against Alzheimer’s disease (Jick et al. 2000;  
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Figure 1.2 Molecular structures of 3-hydroxy-3-methylglutaryl- coenzyme A 
reductase inhibitors.  
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Wolozin et al, 2000). Statins could substantially reduced the risks of dementia and 
Alzheimer’s disease either by delaying its onset, or by opposing specific or general age-
related changes that resulted in cognitive impairment (Jick et al, 2000). Moreover, the 
beneficial effects of statins on Alzheimer’s disease were found to be correlated with the 
metabolism of amyloid precursor proteins (APPs) and β-amyloid peptides Aβ42 and 
Aβ40 (Baskin et al. 2003). Fassbender et al. (2001) found that simvastatin showed a 
strongly reversible reduction of cerebral Aβ42 and Aβ40 levels in vivo in the 
cerebrospinal fluid, and in vitro in brain homogenate. Simons et al (2001) found that after 
treatment with simvastatin in Alzheimer’s patients, these Aβ42 and Aβ40 were reduced 
in the CSF.  In addition, statins also cause changes in tau protein and apolipoprotein E 
(ApoE) (Naidu et al. 2002;  Meske   et al. 2003).   
                   Statins are also able to reduce the infarct volume in experimental stroke.                   
The mechanism of stroke protection appears to be associated with attenuating the 
inflammatory cytokine responses that accompany cerebral ischemia, and possessing 
antioxidant properties that likely ameliorate ischemic oxidative stress in the brain, and 
further improving endothelial function in the absence of significant changes in serum 
cholesterol levels (Williams et al. 1998; Gerard et al.1997). By administering different 
doses of atorvastatin for 2 weeks, Laufs et al. (2000) found that atovastatin protected 
wild-type mice from cerebral ischemia by up-regulating eNOS mRNA expression in both 
aortas and in platelets. In his study, atorvastatin was found to reduce the plasma levels of 
platelet factor 4 (PF4) and ß-thromboglobulin (ß-TG) in wild type mice but did not alter 
plasma levels of PF4 or ß-TG in eNOS knockout mice. These findings suggested that 
effects of atorvastatin on platelet activity were mediated by eNOS because the plasma 
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levels of PF4 and ß-TG were not affected by statin treatment in eNOS knockout mice. So, 
it was concluded that the neuroprotective mechanism of atorvastatin is predominantly 
mediated by NO-dependent effects of statins on decreased hemostasis of blood and 
increased blood flow. Similar results were obtained by Freedman et al. (1997) that NO 
released from activated platelets markedly inhibited platelet recruitment and thus may 
limit the progression of intra-arterial thrombosis.   
                NO is an important mediator of vascular homeostasis and blood flow (Palmer  
et al., 1987; Radomski et al., 1990;  Huang  et al., 1995;  Furchgott  et al., 1980; Ignarro 
1990). Huang et al. (1996) found that mice that lack the gene for eNOS are relatively 
hypertensive and exhibit larger cerebral infarctions after middle cerebral artery (MCA) 
occlusion. Administration of NO donors or eNOS substrate increased protection against 
cerebral ischemia (Dalkara  et al., 1994;  Zhang  et al., 1994;  Morikawa  et al., 1992).  
More directly Endres et al. (1998) performed similar experiments in eNOS-deficient 
mice. They found that treatment with simvastatin had no effects on cerebral blood flow 
(CBF), infarct size, or neurological deficits in eNOS-deficient mice. Moreover, the 
percent reduction in regional cerebral blood flow (rCBF) during ischemia was not 
different between simvastatin and vehicle-injected eNOS deficient mice, and serum 
cholesterol levels were not significantly affected by treatment with simvastatin. The 
beneficial effects of simvastatin were absent in eNOS-deficient mice indicating that most 
if not all beneficial effects are mediated by eNOS. Moreover, the levels of nNOS and 
iNOS mRNA were not significantly different in wild-type and eNOS-deficient mice and 
were not changed after simvastatin treatment. The mechanism of protection may be 
associated with augmented blood flow owing to up-regulation of eNOS by simvastatin 
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but may also stem from other known NO-mediated effects such inhibition of platelet 
aggregation or leukocyte adhesion.   
 
 
1.2 Dopaminergic systems: Dopamine receptors and transmission 
1.2.1   Dopamine (DA) receptors characteristics and their distribution in the brain.   
                 DA receptors belong to the G-protein-coupled-receptor (GPCR) superfamily, 
and are divided into two major subtypes: D1 and D2 subfamilies that differ in the 
coupling to G-proteins, distribution in the central nervous system (CNS), and their 
pharmacological characteristics. With the help of gene cloning procedures, three novel 
DA receptor subtypes were characterized over the last ten years: D3,  D4, and D5 (Sokoloff  
et al., 1990; Van et al., 1991; Sunahara et al., 1991).  
                    D1 receptor subfamily includes the “classical” D1 receptor (also called the 
D1A receptor) and D5 receptor (also called D1B receptor) (Tiberi et al 1991). The 
difference between them is basically in primary amino acid sequence and anatomical 
distribution, however; they bind the same receptor-selective agonists and antagonists with 
similar affinity. The D2 receptor subfamily includes the “classical” D2, and also the D3 
and D4 receptors. These D2-like receptors exhibit a variety of pharmacological, structural 
and functional similarities (Civelli et al 1993; Gingrich et al 1993; Jackson et al 1994).  
                 The structure of the D1 receptor deduced by hydropathic analysis is consistent 
with that of G-protein coupled receptors (GPCR), with seven hydrophobic domains 
predicted to traverse the plasma membrane (Sunahara et al., 1991). Among these 
domains, the amino acids are thought to be in the α-helical configuration. Asparagine-
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linked glycosylation sites are found on the amino terminal domain and the second 
extracellular loop (Figure 1.3).    
                  The D1 receptor has a relatively small third cytoplasmic loop, similar to other 
biogenic amine receptors which are coupled to the stimulatory guanyl nucleotide binding 
protein Gs (Dohlman et al., 1991; Strader et al., 1989). Activation of D1 receptor results 
in elevation of cAMP levels, leading to stimulation of cAMP-dependent protein kinase, 
inhibition of voltage-dependent K+ channels with subsequent neuronal excitability.  
                 D5 receptor is also isolated and cloned from human genomic DNA libraries; its 
cDNA encodes a 477 amino acid protein that has seven transmembrane domains, a 
glycosilation site in the N-terminus, a cAMP-dependent phosphorylation site in the third 
cytoplasmatic loop, and a long residue in the C-terminus, that exhibits high homology to 
the D1 receptor. When D5 receptor is expressed in mammalian cells, it is also functionally 
coupled to the activation of adenylate cyclase, and GABA receptor-mediated activity 
through both second messenger cascades as well as through direct receptor-receptor 
interactions (Yan  et al 1997; Liu et al. 2000).  
                 Among D1 receptor subfamily, D1 receptor is the most widely distributed 
central DA receptor. In the cerebral cortex, it is largely represented in the prefrontal 
cortex, anterior cingulated, orbital, insular, piriform, and entorhinal cortex, 
predominantly V and VI layers. In addition to cerebral cortex, D1 receptor is also located 
in striatum, accumbens shell, anterior olfactory nuclei, hippocampus, septum, thalamic 
and hypothalamic nuclei, hindbrain nuclei, and amygdaloid nuclei, etc (Fetsko  et al., 
2003; Porzio et al., 1999;Blandini  et al., 2003).  In contrast, the D5 receptor is very 
restrictedly expressed in the hippocampus, enthorinal and prefrontal cortex, basal ganglia, 
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and lateral nucleus and hypothalamic nuclei (Ariano et al., 1997; Ciliax et al., 2000; 
Tiberi et al. 1994). Since D1 and D5 receptors are structurally similar to each other, their 
characteristics are also very similar (Table 1.2).  
                There are three main types of D2-like receptor: D2, D3, and D4, among which 
D2 receptor was the first member in the family to be cloned from rat genomic library. 
Cloned human D2 receptor was found to be 96% identical in amino acid sequence to that 
of the rat (Toso et al., 1989; Grandy et al., 1998; Selbie et al., 1989; Stormann at al., 
1990). Compared with D1 receptor subfamily, D2 receptor contains a large third 
cytoplasmic loop a short carboxyl terminal tail and three glycosylation sites in the amino 
terminal region (see Figure 1.4).  
                 The main structural difference between the D2-like and the D1-like receptor 
subfamilies is that the C-terminus of the D2-like receptors is rather small and they have 
the large third cytoplasmic loop between transmembrane regions 5 and 6 and some short 
carboxyl termini, structural motifs that are characteristic of Gi/o-coupled receptors. In 
contrast to D1 receptor subfamily, activation of Gi/o-coupled receptors lead to inhibition 
of adenyl cyclase resulting in a reduction in cAMP level (Senogles 1994; Toso et al., 
1989).   
                 The distribution of D2 receptor mRNA has been widely studied. Highest levels 
are observed in neostriatum, especial in larger cells of external globus pallidus, pole and 
core of nucleus accumbens and olfactory tubercle, as well as in dopaminergic neurons in 
the substantia nigra pars compacta, ventral tegmental area, midbrain and hindbrain.  
                D3 receptor, which was cloned by Sokoloff et al. (1990), shares 52% overall 
homology and 75% transmembrane homology with the D2 receptor. Analysis of D3  
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Figure 1.3. D1 receptor structure 
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receptor mRNA distribution in the brain shows that it is much less abundant than D2 
receptor. It was found to a greater extent in hypothalamic and limbic nuclei such 
olfactory tubercle, islands of Calleja, hippocampus, nucleus accumbens, and bed nucleus 
of the stria terminalis than in the basal ganglia (Bouthenet  et al, 1991; Moine et al., 
1995). Minimal expression is also observed in the caudate-putamen, hypothalamus, 
septum, and geniculate bodies. D2 receptor and D3 receptor have similar pharmacological 
profile (Freedman et al., 1993; Mackenzie et al, 1994; Malmberg et al, 1993;  Sokoloff et 
al, 1990) such as mediation of adenylate cyclase inhibition.  
                   Like D3 receptor, D4 receptor appears to be expressed at a lower level than 
the D2 receptor. Cloning and expression of this receptor was accomplished in several 
stages (Van Tol et al., 1991). The highest D4 receptor mRNA expression is located in the 
frontal cortex, midbrain, amygdala, medulla, with lower level in the striatum, olfactory 
tubercle, and hypothalamus (Van Tol et al., 1991) but it was also found in substantia 
nigra pars compacta (Missale et al., 1998). More detailed properties are shown in Table 
1.2.  
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Figure 1.4 D2 receptor structure  
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1.2.2. cAMP---- the hallmark for the functional measurement of G-protein coupled   
receptors.  
               G-protein coupled receptors that bind guanine nucleotides GDP and GTP    
include three subunits: Gα, Gβ, and Gγ. Normally in the inactive state, Gα is bound to 
GDP. As one of the members of G-protein coupled receptors, when ligand such as a D1 
receptor agonist binds to D1 receptor, an allosteric change takes place in D1 receptor. It 
causes GDP to be phosphorylated to GTP. GTP activates Gα causing it to dissociate 
from Gβ and Gγ which remain linked as a dimer. Activated Gα in turn activates adenylyl 
cyclase--an enzyme in the inner face of the plasma membrane which catalyzes the 
conversion of ATP into the "second messenger" cyclic AMP (cAMP). There are two 
main types of Gα subunits: Gαs (stimulatory of adenylyl cyclase), Gαi (inhibitory of 
adenylyl cyclase). When Gαs is activated, for example D1 receptor is stimulated by its 
agonist, Gαs stimulates adenylyl cyclase so that more ATP is converted into cAMP 
(Figure 1.5). In contrast to activation of D1 receptor, when D2 receptor is combined with 
its agonist, Gαi will be activated so as to inhibit adenylyl cyclase and lower the level of 
cAMP (Stoof  et al 1981; Stoof et al. 1982; Huff. 1997).  
                As an intracellular second messenger that is triggered by hormones or other 
signaling molecules, cAMP exerts hormonal responses such as the mobilization of stored 
energy, conservation of water by the kidney, Ca2+ homeostasis, increased rate and force 
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1.2.3. Dopaminergic pathways and their functions.    
                  Dopaminergic neurons, which synthesize and excretes dopamine, are located 
in the ventral boundary zone between the midbrain and hindbrain, migrate and form nine 
cell groups (A8-A16). The three major nuclei--substantia nigra, ventral tegmental area 
(VTA) and hypothalamic nuclei--project to nearly all the areas of the brain. The 
projection zones of dopaminergic terminals indict the functional role of dopaminergic 
neurons and reflect their variability. Basically, there are in total four dopaminergic 
pathways in the brain (Figure 1.6): nigrostriatal pathway, mesolimbic pathway, 
mesocortical pathway, and tuberoinfundibular pathway (Jucaite 2002).  
                These nigrostriatal pathway that project from the substantia nigra to 
subcortical structures (striatum)-caudate nucleus and putamen is the most profused 
among the four dopaminergic patyways, and constitute about 80% of the dopaminergic 
systems. As part of a system called the basal ganglia motor loop and one of the major 
dopamine pathways in the brain, it is particularly involved in the production of 
movement.  Loss of dopamine neurons in the substantia nigra above 75% produces the 
main pathological features of Parkinson disease (PD) and leads to a marked reduction in 
dopamine function in this pathway. This pathway is also implicated in tardive 
dyskinesia, one of the side effects of antipsychotic drugs.  
             The second massive projection is from ventral tegmental area (VTA) which 
forms two pathways: mesocortical pathway and mesolimbic pathway, which are 
classically correlated to reward and addiction (Salamone et al., 1996; Spanagel et al., 
1999). Historically the mesolimbic and the mesocortical dopamine systems have been 
considered as the regulatory site for mood, emotion, and the control of visceral activity, 
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and as such, are the natural sites to explore the role of dopamine in reward. The 
mesocortical pathway connects the ventral tegmentum to the cortex, particularly the 
frontal lobes. As an essential part of the normal cognitive function of the dorsolateral 
prefrontal cortex (part of the frontal lobe), it is also thought to be involved in 
motivational and emotional responses. Mesocortical pathway is also thought to be 
associated with the negative symptoms of schizophrenia, which include avolition, alogia 
and flat affect (lack of emotional response). The mesolimbic pathway links the ventral 
tegmentum area to the nucleus accumbens in the limbic system. This neural pathway is 
recognized to produce pleasurable feelings and is related to the feelings of desire and 
reward, particularly because of the connection to the nucleus accumbens (Salamone 
1991; Le Moal et al 1991). Thus the mesolimb cortical systems are implicated in reward, 
reinforcement and addiction. Administration of psychostimulants and drugs of abuse has 
been shown to increase dopamine release in the mesolimbic area, whereas withdrawal of 
these drugs resulted in a reduction of dopamine (Chiara 1995; Moal et al., 1991; Ramsey 
et al., 1992; Wise et al., 1994). Both D1 and D2 receptors are involved in reward and 
reinforcement behavior, with the agonist stimulating and antagonists inhibiting the 
behavior (Franklin et al., 1983; Kornetsky et al., 1981). Antipsychotic medications, 
though poorly understood, disrupt dopamine function in this area implying that 
especially an excess of dopamine is linked to psychosis and the 'positive symptoms' of 
schizophrenia (Kane et al., 1994; Sigmundson 1994;   Seeman et al., 1995; Seeman et 
al., 1993; Sokolowski et al 1994; Swerdlow et al 1992). Antipsychotic medication is 
therefore believed to have its effect by blocking dopamine receptors in this pathway. It 
is also generally accepted that mesolimbocortical dopamine D1 and D2 receptors play a 
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role in learning and memory (Sawaguchi et al., 1991;  Sawaguchi, T  et al., 1994;  
Arnsten et al., 1995; Levin et al., 1995). 
                 The tuberoinfundibular pathway, which is formed by hypothalamic 
dopaminergic neurons function mainly to suppress prolactin secretion from the pituitary 
gland. If dopamine is blocked in the tuberoinfundibular pathway, increased prolactin 
release from the pituitary gland leads to hyperprolactinemia. This can cause abnormal 
lactation (even in men), disruptions to the menstrual cycle in women, visual problems, 
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1.3. The  central dopaminergic systems and neurological disorders.  
                The nigrostriatal dopaminergic pathway is essential for movement control. 
Bernheimer et al, (1965) found that the motor deficits in PD patients were associated 
with depletion of striatal dopamine. The loss of dopamine in the striatum resulted in 
difficulty to initiate movements, bradykinesia, inability in automatic movements and 
postural adjustments, tremor, and rigidity (Marsden et al, 1994). Lesions of the 
nigrostriatal pathway have also been found to alter orientating behavior (Dunnett  et al., 
1982) and visual discrimination in a choice reaction-time  (Carli et al, 1985; Brown  et 
al, 1991).   
                Because of shortage of striatal dopamine in Parkinson’s disease (PD), 
replacement of dopamine is used as the main treatment therapy in PD. Dopamine is 
synthesized in nerve cells from L-tyrosine through an intermediate 
dihydroxyphenylalanaine (L-DOPA) in a two-step process. The first, rate limiting step is 
catalysed by tyrosine 3-monoxygenase (tyrosine hydroxylase or TH). The second step is 
catalysed by aromatic L-amino acid decarboxylase (L-DOPA decarboxylase) (Bracco et 
al, 1991; Haavik 1997). When levodopa is taken orally, it crosses through the "blood-
brain barrier." Once it crosses, it may be converted to dopamine. The resulting increase 
in brain dopamine concentrations is believed to improve nerve conduction and assist the 
movement disorders in Parkinson's disease (Carter et al, 1989). Levodopa remains the 
most effective treatment for Parkinson's disease (Lang et al, 2004).                  
                 In addition to L-DOPA therapy, dopamine receptor agonists are recognized to 
be effective therapy for PD. While initially believed to be effective only as adjunct 
treatment to L-dopa, dopamine receptor agonists are now accepted as a primary means 
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of treating motor symptoms in early PD with a decrease in the incidence of dyskinesia 
(Nutt et al., 2000; Olanow et al., 2000). In addition to their symptomatic benefit and 
their ability to prevent or delay motor complications, through stimulating the dopamine 
receptors, protecting against cerebral ischemia and apoptotic cell death and free radical 
scavengers, reducing dopamine cell loss in PD patients, and increasing cell survival, 
dopamine receptor agonists also exert a neuroprotective action (Gassen et al., 1998; Kin 
et al., 2001; Kitamura et al., 1998; Sethy et al., 1997). Though a lot of work and studies 
have been done about the effects of dopamine receptors and their agonists on PD, some 
of the mechanisms remain unknown, and more explorations need to be done.          
                 In addition to motor dysfunction, PD patients were found to have cognitive 
deficits. Usually PD patients with serious difficulties in motor initiation are recognized 
to be associated with ideomotor apraxia, subsequently resulting in slowness in initiating 
motor action and affect the generation of ideas and plans (Berardelli et al, 1986; 
Goldenberg et al, 1986). The organization of behaviour was obviously impaired in such 
PD patients and complex but not simple behaviour was affected pronouncedly 
(Goldenberg et al, 1986; Viallet et al 1984). Klockgether et al, (1994) demonstrated that 
the ability to use non-visual feedback in PD was impaired during the execution of arm 
movements. Another central alteration in PD is correlated to executive-type behaviour 
based on a continuous updating of information. Owen et al. (1996) indicated that this 
type of cognitive deficit would be considered as related to working memory deficit that 
contributed to reasoning by storing; information was taken into account rapid changes in 
the external context of the motor behaviour.  
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                 Schizophrenic patients also exhibit cognitive deficits (Gold et al. 1995) 
though the nature of the contribution of dopamine and its receptors to schizophrenia are 
still not clearly understood (Scatton et al. 2000). The focus of the role of dopamine in 
the pathogenesis of schizophrenia derived from the correlation of antipsychotic effects 
of neuroleptics acting as efficient blockers of dopamine receptors, as well as the 
observation of mental confusion and exacerbation of psychosis induced by 
amphetamine-like drugs (Angrist et al., 1984; Deutch 1992; Deutch 1993). More recent 
evidence (Silbersweig et al., 1995) suggested that the hyperactivity of subcortical 
dopaminergic systems underlie the positive symptoms of schizophrenia, while the 
hypoactivity of the cortical dopaminergic systems underlies the negative symptoms. 
Actually, a large majority of this type of patients show difficulties in movement 
initiation correlated to hyperactivity that contributes to cognitive deficits. This type of 
deficit is associated with positive or negative forms of schizophrenia, which may reflect 
opposite changes in dopamine activity at the cortical level. In schizophrenia patients 
with negative symptoms, the hypoactivity was associated with dopamine decrease in the 
prefrontal cortex (Berman et al, 1990), thus Willner (1997) proposed an alternative 
therapy with dopamine receptor antagonists to stimulate dopaminergic transmission in 
those patients.  Generally speaking, schizophrenia is considered to be associated with a 
local alteration in cortical dopaminergic transmission, and it is inferred that alterations in 
dopamine signaling could affect information processing. To some extent, we might 
expect that correcting such defects in dopamine transmission would help to improve 
cognitive deficits occurred in schizophrenic patients.  
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              Dopaminergic systems are also found to be involved in the reward system.  
Olds et al (1954) provided the first evidence for brain ‘reward’ system by intracranial 
self-administration of electrical stimulation. ‘Reinforcement’ may be defined as ‘any 
event that increases the probability of a subsequent response’ while ‘reward’ as ‘with 
some positive affective coloring such as pleasure’ (Tarpy 1997;  Salamone et al., 1997). 
The two terms ‘reinforcement’ and ‘reward’ are often used interchangeably. Wise et al, 
(1978, 1982) was the first to propose the role for increased dopamine neurotransmission 
in hedonism caused by rewards. Blockade of dopamine receptors with neuroleptics 
impairs operant reinforced responding to natural agents such as food and water. These 
findings indicated that dopamine plays a major role in the brain reward circuitry 
(Schultz 1998). Current theories agree that dopamine has little effect in the hedonic 
aspect of reward, but is associated with anticipatory respects and invigorates a variety of 
motivated behaviors (Salamone et al., 1997; Ikemoto et al., 1999; Horvitz 2000). It is 
quite clear that dopaminergic pathway is activated not only by the natural rewards but by 
a variety of types of abused drugs. With both natural rewards and abused substances, 
dopamine antagonists block the reinforcing effects. Westerink et al. (1995), Salamone 
(1996), and Di Chiara (1999) found that dopamine increased the response to natural 
rewards as well as addictive drugs. Psychostimulants such as amphetamine and cocaine 
(McBride  et al., 1999;  Di Chiara 1999), were all found to increase the release of 
dopamine in a regionally specific manner by inhibiting uptake, resulting in up-regulation 
of extracellular dopamine levels and leading to the rewards; while long-term 
neuroadaptation in dopaminergic neurons were also found following stimulant 
administration (Ungless et al., 2001; Robinson et al., 2001a).   
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               Although the notion that dopaminergic neurons consist of the ‘pleasure center’ 
of the brain is popular (the National Institutes of Drug Abuse web site: 
http://165.112.78.61/Teaching2/teaching.html), more refined reports have led to more 
sophisticated reward hypotheses (Wise et al., 1996; Salamone et al., 1997;  Berke et al., 
2000). Ikemoto et al. (1999) proposed a hypothesis that dopamine was involved in the 
learning of cues associated with reward. Robinson et al. (1993) and Berridge et al. 
(1998) have suggested that addictive behavior arose from an inappropriate development 
of incentive salience, a process linked to dopamine. In 1995, Schultz et al. (1995) 
reported that when reward did not work in the course of a learning procedure, the 
discharge of dopaminergic neurons stopped at the moment of the predicted event, which 
could encode an error signal between the prediction and the actual occurrence of reward. 
Later on, Schultz found that in monkeys, decreases or increases in dopaminergic 
transmission provided an error signal for unexpected rewards that affect learning 
(Schultz W et al. 1997; Schultz 1998).   
              Most of these findings and hypotheses are based on the observed changes in 
dopamine and its receptors during reward and the psychological theories of reward and 
motivation processes. More explorations to clarify the role of dopamine in future 
experiments would be focused on the dopamine and its receptors. For example, Nicola et 
al. (2000) has showed that by activating different receptor subpopulations particularly 
D1 receptor, dopamine would modulate different aspects of reward processing. While 
some findings and mechanisms have been figured out, the precise function of dopamine 
in the brain reward system has yet to be resolved probably due to the complexity of the 
dopaminergic systems which may play multiple roles in the reward circuitry.                
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1.4. Animal models of Parkinson disease.  
             The prime cause of motor symptoms in PD is basically recognized as a loss 
of nigral dopaminergic neurons and consequent to dopamine depletion in the basal 
ganglia. Based on this knowledge, several PD animal models are produced, among which 
systemic administration of MPTP and stereotaxic injection of 6-hydroxydopamine (6-
OHDA) models are most widely used.   
            1-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) was discovered in 
1982, when a group of drug addicts developed sub-acute severe Parkinsonism (Langston 
et al., 1983; Ballard et al., 1985) after self-administration of  synthetic heroin--1-methyl-
4-phenyl-4-propionoxypiperidine that was contaminated by a by-product—MPTP. MPTP 
is highly lipophilic and easily crosses the BBB. Once in the brain, it is converted to 1-
methyl-4-phenylpyridinium (MPP+) by monoamine oxidase B in glia. Dopamine neurons 
may accumulate MPP+ via the dopamine transporter. MPP+  damages  complex I of the 
electron transport chain in the mitochondria resulting in a reduction of ATP generation 
and causing the production of reactive oxygen species (ROS) and so inducing apoptotic 
death of dopamine neurons (Kitamura et al. 2000;  Kitamura et al. 2003; Speciale et 
al.2002). Systemic administration of MPTP to non-human primates such as monkey may 
produce a Parkinsonian syndrome that is very similar to that seen in Parkinsonian patients 
including resting tremor, rigidity, and slowness of spontaneous movement among other 
symptoms. Meanwhile MPTP treated-primates will exhibit a good response to L-DOPA 
and dopamine receptor agonists. However rodents, such as rats, are less sensitive than 
primates to MPTP neurotoxicity because rats have been found to show little dopamine-
cell degeneration when exposed to MPTP in part owing to the high capacity for vesicular 
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sequestration of MPTP (Staal et al. 2000; Sundstrom et al.1997). In rodents, the 
appearance of Parkinsonian behavior requires a complete blockade of the dopamine 
response by D2-receptor antagonists, and incomplete dopamine depletion is insufficient. 
Hence, MPTP-treated monkeys are recognized as a more suitable model of sporadic PD 
(Kopin et al. 1988; Langston et al. 1986). However, among rodents, C57BL/6 strain of 
mice are the most sensitive to MPTP, and because of the economical, logistical and 
ethical constraints that are related to research on primates, MPTP-treated mice are also 
accepted as a useful model (Przedborski et al. 2001; Marco et al. 2001; Kitamura et al. 
2003).  
              In addition to the MPTP model, rats with 6-hydroxydopamine (6-OHDA) lesion  
is another widely accepted PD model since it was found to be a selective toxin to 
dopaminergic nerurons (Ungerstedt 1971). The model involves a unilateral injection of 6-
OHDA into  the medial forebrain bundle to lesion the nigrostriatal pathway. Also 6-
OHDA lesioned PD model includes injection of the 6-OHDA directly into the striatum to 
create retrograde degeneration of substantia nigra neurons. Rats with bilateral 6-OHDA 
lesions show all of the essential motor syndromes of PD as mentioned above; however, 
rats lesioned bilaterally with 6-OHDA are not widely used since they need intensive 
nursing care (Schwarting et al. 1996). A major advantage of the unilateral model is a 
quantifiable rotational behavior when challenged by amphetamine or apomorphine (Beal 
2001; Deumens et al. 2002).  
               In addition to the two main PD animal models mentioned above, there are 
some other PD models such as rotenone and recent gene-targeting and transgenic animal 
models.  
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                   Rotenone, a naturally occurring pesticide, derived from the roots of several 
tropical and subtropical plant species belonging to the genus Lonchocarpus or Derris is an 
inhibitor of mitochondrial complex I. When rats are exposed to rotenone through jugular 
vein cannulation, they show features of PD such as bradykinesia, postural instability, 
unsteady gait, and tremor, and they showed nigrostriatal dopamine degeneration and the 
formation of α-synuclein-immunoreactive cytoplasmic inclusions similar to Lewy bodies 
(Betarbet et al. 2000).  
                  With the development of transgenic technique, a novel PD model was 
produced by expressing mutant and normal forms of α-synuclein in drosophila (Feany et 
al. 2000). Flies overexpressing either wild type or mutant α-synuclein show an age-
dependent loss of dorsomedial neurons that stained for tyrosine hydroxylase (TH). It is 
also found that the α-synuclein stained inclusions are very similar to Lewy bodies under 
light microscopy and electron microscope (EM).  
                Among all the PD animal models mentioned above, the injection of 6-OHDA 
leads to the greatest loss of dopaminergic neurons in both the substantia nigra and 
striatum, but each type of model has its own characteristics. The hemiparkinsonian model 
in rats induced by 6-OHDA is the simplest one and good for initial studies.  
 
 
1.5. Nitric oxide synthases and their clinical relevance.  
               Nitric oxide (NO) is a multifunctional agent acting as an important signaling 
molecule in physiological processes such as neuronal communication, host defence, and 
regulation of vascular tone (Gross et al., 1995). NO, through the action of nitric oxide 
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synthase (NOS), is formed from the terminal guanidine nitrogen of L-arginine through an 
intermediate, N-hydroxy-L-arginine, yielding L-citrulline (Palmer et al., 1988; Hemmens 
et al., 1998). NO may exert complex actions in organ systems that are both   
physiologically and pathophysiologically developmental processes (Wingrove et al., 
1999; Nathan et al., 2000; MacMicking et al., 1997; Bogdan et al., 2000).  
                NOS exists in three isoforms: nNOS (also known as type I or NOS-I) is found 
in neuronal tissue, iNOS (also known as type II or NOS-II) is the inducible form found in 
a  variety of cells and tissues, and eNOS (also known as type III or NOS-III) is 
abundantly found in vascular endothelial cells. The two constitutive isoforms (eNOS and 
nNOS) are calcium-dependent while iNOS is calcium independent (Bogdan 2001; 
Alderton et al, 2001). Although the three isoforms may share a common ancestral NOS 
gene, they differ in term of their main modes of regulation, expression patterns in tissues, 
the average quantity of NO production, and intracellular location (Table 1.3).  
                 NO produced by these three isoforms exhibits different functions, and in 
different physiological process exerts different effects on tissues or cells. As an essential 
molecule in nomal physiology, the functions of NO derived from these three isoforms of 
NOS are complex.  Whether the NO effects are beneficial or harmful depends mainly on 
the degree and time-frame of activity, the eliciting signal(s), the amplitude and duration 
of the production of NO, and the tissue microenvironment and tissue distribution 
(Bogdan 2001; MacMicking et al, 1997).iNOS, which produces NO in high concentration 
(µM), is mainly present in inflammatory cells after induction by cytokines and other 
inflammatory mediators (Albrecht et al 2003; Hernandez-Pando et al, 2001). Nathan 
(1992) and Kolb et al (1998) indicated that in autoimmunity, iNOS-derived NO was 
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originally taken as a tissue-damaging molecule produced by activated macrophages 
infiltrating the parenchyma; however in some studies, beneficial effects have also been 
reported (McCartney-Francis et al, 2001; Gilkeson et al, 1997).  
                Contrasting to iNOS, the NO derived from nNOS and eNOS is normally in low 
concentrations (nM) for their physiological purpose (Albrecht et al 2003). nNOS is 
mainly generated from neurons and skeletal muscles cells but eNOS is mainly from 
endothelial cells and some epithelial cells. Some reports showed that eNOS derived NO 
plays a protective role by inhibiting platelet adhesion and aggregation to the endothelium 
and inducing vasorelaxation (Radomski et al 1993; Granger et al 1996).  Harrison (1997) 
and  Heeringa et al, (2002) found that eNOS derived NO could provide a beneficial effect 
by reacting with other free radicals such as superoxide. To date, it is well established that 
NO and its synthases are involved in a variety of neurological diseases such as 
neurodegeneration, stroke, ALS and multiple sclerosis. Generally speaking, neurons are 
highly susceptible to NO that may lead to necrosis and apoptosis. Some recent findings 
showed that large amount of NO produced by nNOS may play some subtle roles in 
impairing the integrity of BBB and producing reactive changes in astrocytes which would 
propagate injury, and also those NO and superoxide anion is involved in the nuclear gene 
damage in cerebral ischemia by the formation of peroxynitrite (Cui et al., 1999; Cui et al., 
2000; Huang et al., 2000). The increased level of extracellular glutamate induced by brain 
injury activated neuronal NOS (nNOS) via calcium influx (Dawson et al., 1991; Sheng et 
al., 2000). These findings were also supported by evidence that an elevated level of NO 
in brain tissue occurred after cerebral ischemia-reperfusion and spinal cord injury (Zhang 
et al., 1995; Cherian et al, 2000; Jones et al, 1995; Kumura et al, 1996). In a mouse stroke 
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model, treatment with 7-nitroindazole (7NI), an inhibitor of nNOS, or knocking out 
nNOS was found to protect neurons from death and prevent neurons from stroke attack 
(Yoshida et al., 1994; Panahian et al., 1996; Huang et al., 1994; Eliasson et al., 1999). 
NO was also found to induce the apoptosis of a variety of types of cultured cells and may 
contribute to the death of neurons in ischemia stroke. It is believed that excessive NO 
exacerbates cellular proteins and triggers an apoptotic cascade involving the release of 
cytochrome C and activation of caspases. In nNOS null mice, a deficit in neuronal NO 
production slowed the apoptotic cell death development among stroke model, and bcl-2 
levels reduced in association with delayed activation of effector caspases (Elibol et al., 
2001).  
              NO is also found to play a key role in Alzheimer’s disease. Increased NO level 
produced by iNOS is closely associated with the amyloid β (Aβ40 and Aβ42) proteins 
which are hallmarks of Alzheimer’s disease (Haas et al., 2002; Michael et al., 2002). 
Amyloid β protein stimulated microglia induced NO-dependent apoptosis and hence 
enhanced neurotoxicity in Alzheimer’s disease, indicating that the NO-mediated pathway 
stimulated by microglia may play a key role in the disease processes (Monsonego et al., 
2002; Monsonego et al., 2003).  
                There is now sufficient evidence that support the idea that NO occurs in the 
substantia nigra in PD and that NO contributes to dopaminergic cell degeneration (Fahn 
et al., 1992). It is generally accepted that excessive NO may damage dopaminergic 
cellular components such as lipids, proteins and DNA, and accelerate as the disease  
advances. A large amount of evidence shows that oxidative stress and oxidative damage 
occurring in PD are linked to NO.  By reacting with superoxide to form peroxynitrite, 
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Table 1.3. Biochemical properties, regulation, and function of nitric oxide synthases.  
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which acts as not only an oxidizing agent but also degrades to hydroxyl radicals among 
other species, NO exerts its toxicity on neurons (Beckman et al., 1990). Hunot et al. 
(1996) found that there was increased immunoreactivity for iNOS in the substantia nigra, 
as a result of glial cell activation. By mediating iron release from ferritin, NO was found 
to contribute to neuronal degeneration (Reif et al., 1990). Toxicity of NO was involved in 
DNA damage leading to products such as 8-hydroxyguanine and increase in DNA single-
strand breakdown (Byun et al., 1999). NO was also found to produce inhibition of 
complex I and IV of the mitochondrial respiratory chain, which is recognized to 
exacerbate the cell damage (Bolanos et al., 1997; Clementi et al., 1998; Bolanos et al., 
1996). Some indirect findings similarly implicates that NO is involved in the 
mechanisms of nigral cell degeneration. By inhibiting nNOS using 7-nitroindazole (7-
NI), a selective inhibitor of nNOS, striatal dopamine depletions and loss of tyrosine 
hydroxylase-positive neurons were obviously prevented in the substantia nigra of MPTP-
treated baboons (Hantraye et al., 1996; Schulz et al., 1995). In transgenic mice, by 
knocking out the nNOS gene, mutant mice were significantly resistant to MPTP-induced 
neurotoxicity compared with wild-type littermates (Przedborski et al., 1996; Wu et al., 
2002).  In addition to nNOS, other studies showed that iNOS have also been implicated 
to contribute to the dopaminergic neurons degeneration (Liberatore GT et al., 1999). The 
up-regulation of iNOS paralleled MPTP-induced dopaminergic neurodegeneration; 
however, by knocking out the iNOS gene, the mutant mice were significantly more 
resistant to MPTP than their wild-type littermates (Liberatore GT et al., 1999). Similar 
results were obtained and offered a potential therapeutic intervention (Wu et al., 2002).  
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                  Some recent findings also showed that oxidative stress might be associated 
with the impairment of the ubiquitin-proteasome system (UPS), a key component in the 
pathogenesis of PD (McNaught et al., 2001), and in turn, impairment of the UPS may 
lead to oxidative stress so that a vicious circle forms and enhances the toxicity on 
dopaminergic neurons (Lee et al., 2001; Hyun et al., 2002).  
                  In contrast to nNOS and iNOS, the roles of eNOS in diseases are usually 
recognized as beneficial factors. Normally it is thought that impaired eNOS activity and 
endothelial dysfunction are seen in various diseases, including atherosclerosis (Arnal et 
al 1999), hypercholesterolaemia (Feron et al 1999), and hypertension (Panza JA et al 
1997). Some evidences showed that the up-regulation of eNOS protects against 
ischemia/reperfusion injury under (patho) physiological conditions. After gene transfer,  
the up-regulation of eNOS exerted protective effects against ischemia/reperfusion injury 
(Akyurek et al 1996). In the study of MCAO mice model, eNOS-/- mice show decreased 
brain-derived neurotrophic factor (BDNF) expression, a very useful and beneficial 
neurotrophic factor, in the ischemic brain compared with wild-type mice. Also eNOS, the 
downstream mediator for VEGF and angiogenesis, influenced progenitor cell 
proliferation, neuronal migration, and neurite outgrowth, and so affected functional 
recovery after stroke (Chen et al 2005). Furthermore, Asahi et al (2005) found that by 
upregulating endogenous tissue plasminogen activator (tPA) and eNOS expression and 
enhancing clot lysis, simvastatin and atovastatin provide additional beneficial effects and 
exerted neuroprotection against brain ischemic injury in a mouse model of embolic focal 
ischemia.   
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                In addition to stroke, eNOS also have been indicated to be closely correlated to 
Alzheimer’s disease (AD). Gentiles at al (2004) found that globular form of ß-amyloid 
peptides induced an endothelial NO dysfunction through reducing eNOS enzymatic 
activity in AD patients. This endothelial NO dysfunction induced by globular ß-amyloid 
peptides probably was due to an alteration of intracellular Ca 2+ homeostasis, which 
might lead to activation of calcium-dependent group of PKC with a consequent change 
of the eNOS phosphorylation pattern. This effect might show the link among vascular 










Chronic treatment with simvastatin in SD rats.   
 
                                                              
 
        2.1. Introduction:  
                   Statins reduce serum low-density lipoprotein (LDL) cholesterol by inhibiting 
the rate-limiting enzyme, hydroxymethylglutaryl-coenzyme reductase, in cholesterol 
synthesis. These drugs are now widely used clinically for the prevention of atheromatous 
disease. Meta-analyses of data from major clinical trials have shown that the risk of 
ischaemic heart disease events is reduced by 60% and stroke by 17% (Law et al., 2003). 
The statins are also being recognised to have potential application in peripheral arterial 
disease, end-stage renal disease, diabetes mellitus, and Alzheimer's disease (AD) 
(McKenney, 2003; Vega et al., 2003). In animal studies, statins also appear to be 
beneficial in traumatic brain injury (Lu et al., 2004) and neuroinflammation (Adamson & 
Greenwood, 2003). Despite growing evidence for a role of statins in CNS diseases such 
as stroke and AD, there is relatively little knowledge of their effects in the brain. 
                Current evidence indicates that statins may provide neuroprotection against 
ischaemic damage through endothelial nitric oxide synthase (eNOS)-dependent 
mechanisms (Williams et al. 1998; Gerard et al.1997; Laufs et al, 2000; Endres et al, 
2004). Statins can increase the production of NO directly by increasing eNOS activity or 
indirectly by decreasing factors such as oxidised LDL, oxidised LDL receptor 1, and 
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Rho, which negatively regulate eNOS expression (see Laufs, 2003 for a review). In the 
kidney, the natriuretic and diuretic responses mediated by D1 receptors are attenuated by 
the NOS inhibitor NG-nitro-L-arginine (L-NAME) in anaesthetised rats (Venkatakrishnan 
et al., 2000), while D2 receptor blockade potentiated the renal effects of L-NAME in 
humans (Montanari et al., 1998). In the brain, NO mediates release of dopamine (Hirsch 
et al., 1993; Dominguez et al., 2004). It has also been reported that NO is involved in the 
nicotine-induced burst firing of dopaminergic neurons in the ventral tegmental area of the 
rat brain (Schilstrom et al., 2004), and that these dopaminergic cells also express NOS 
(Klejbor et al., 2004). Therefore, it is interesting to investigate any possible effects of 
statins on the central dopaminergic system. As the first step, the effects of long-term 
statin treatment on D1 and D2 receptor gene expression was studied in Sprague−Dawley 
rats.   
 
 
           2.2 Methods  
           2.2.1  Animals and statins pretreatment           
 
                Sprague-Dawley (SD) rats (Laboratory Animal Center, National University of 
Singapore) weighing 280-300g were obtained and housed 4 or 5 per cage with food and 
water available ad libitum under natural light-dark cycle (approx 12-12h). All 
experiments were carried out in accordance with guidelines set by the National 
University of Singapore (adapted from Howard-Jones, 1985). SD rats were randomly 
divided into five groups: saline treated group (control group), simvastatin (Ranbaxy 
Laboratories, Dewas, India) treated groups at dosage 1.0mg/kg/day, 10mg/kg/day, 
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30mg/kg/day, and pravastatin (30mg/kg/day, Bristol-Myers Squibb, Noble Park, 
Australia) treated group respectively. SD rats from the control group were given oral 
administration of 0.09% saline for 4 weeks. Simvastatin and pravastatin, which were 
grounded and then suspended in 0.9% saline (1.5ml), were given daily by oral 
administration (garage).  
 
               
            2.2.2     Serum cholesterol and triglyceride measurement  
 
              After 4-weeks oral of administration daily, blood samples were collected and 
centrifuged at 1000g for 15 min to obtain the serum. The serum triglyceride and cholesterol 
levels were measured using commercially available assay kits obtained from ThermoTrace 
(Noble Park, Australia).     
         
 
           2.2.3. Preparation of RNA from prefrontal cortex and striata of SD rats.  
                      Rats were killed with CO2 and the prefrontal cortices and striata were 
removed on ice. For RNA isolation, prefrontal cortex and striata tissues were 
homogenized in ice-cold Trizol reagent (1:10 w:v, Gibco/BL) with a polytron 
homogenizen (Janke &Kunkel company, Germany). The homogenate was centrifuged at 
12,000 g for 10 minutes at 4 0C. The supernatant which contained RNA was treated with 
phenol-chloroform. These were caped securely and shaken vigorously by hand for 15 s 
and then incubated at room temperature (23 0C -260C) for 2-3 minutes. Then samples 
were centrifuged at 12,000 g for 15 min at 4 0C. The colorless upper aqueous phase, 
which contained the RNA, was transferred to anther tube and total RNA was precipitated 
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after adding isopropanol followed by incubation at room temperature at 20 0C for 10 min, 
and then centrifugation at 12,000 g for 10 min at 4 0C. The RNA precipitate, often 
invisible before centrifugation, formed a gel-like pellet on the bottom of the tube. The 
RNA pellet was washed with 75% ethanol and then centrifuged at 7500 g for 5 min at 4 
0C and then by suspended in diethylpyrocarbonate (DEPC)-treated water. Finally, the 
RNA concentration was determined spectrophotomerically by measuring the absorbance 
at 260nm.                  
 
 
          2.2.4. Reverse transcription-polymerase chain reaction (RT-PCR). 
                  In order to synthesize single stranded cDNA, extracted RNA (5µg) from the 
brain tissue was incubated at 70 oC for 10 min with oligo-dT(12) primers (Gibcol, BRL, 
Life Technologies, Rockville, Maryland) and then at 48oC for 45 minutes with AMV 
reverse transcriptase (Promega) in the reaction buffer which contained 20 mM Tris-HCL, 
0.5mM dNTP, 10mMDTT, and 2.5mM MgCl2. Double-stranded cDNAs were 
synthesized and amplified in a 100µl PCR reaction mixture with: 1.25 mM MgCl2, 0.2 
mM dNTPs, 20 mM Tris-HCL, 1 unit of Taq DNA polymerase (Gibcol, BRL, Life 
Technologies, Rockville, Maryland), and 0.2 mM of each primer. Each PCR reaction was 
repeated at least 5 times in a Perkin Elmer 2400 thermocycler.  Sense and antisense 
primers for D1/D2 dopamine receptor and β-actin (SD rat) are shown below. β-actin was 
used as a house keeping gene 
.  
D1 (rat) sense 5'-GAT TCC ATC ACC TTC GAT GTG- 3',  
Chapter 2  
 42
D1   antisense 5'-GGT GTC ATA GTC CAA TAT GAC CG-3' (359 bp)  
D2 (rat) sense 5'-CCC TCC TCA TCT TTA TCA TCG-3',  
D2 antisense 5’-GGT CTG TAT TGT TGA GTC CGA A-3’ (410bp) 
β-actin (rat)  sense 5’-ATC TGG CAC CAC ACC TTC TAC AAT GAG CTG CG-3’,  
β-actin antisense 5’-CGT CAT ACT CCT GCT TGC TGA TCC ACA TCT GC-3’   
(870bp)  
PCR denaturing, annealing, and extension reactions proceeded respectively at 94°C for 1 
min, 60°C for 1 min and 72°C for 1 min (β-actin 30 cycles. Loo L.S et al 2002); 94°C for 
30 sec, 60°C for 30 sec, and 72°C for 1 min (D1 receptor: 35 cycles); 94°C for 30 sec, 
59°C for 30 sec, and 72°C for 45 sec (D2 receptor : 35 cycles). (Reuss & Unsicker 2001).  
 
 
         2.2.5. Quantification of PCR products 
                    PCR products were separated by electrophoresis on 1.5% TAE (Tris-CL-
acetate-EDTA buffer) agarose gel, which was stained with ethidium bromide (0.8µg/ml) 
and photographed under UV light. Each lane on the exposed films was scanned using a 
computer-assisted laser scanner and band intensity was measured by NIH image-
processing software using the Viber Lourmat Imaging system. The ratio of the 
corresponding density (e.g. D1/β-actin) was calculated for each sample and used for 
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          2.2.6. Western Blot analysis for D1 and D2 receptors and β-actin                      
                  Male Sprague-Dawley rats (280-300g) were killed followed by decapitation. 
The brains were removed and the prefrontal cortices were taken out rapidly followed by 
dissected over ice and homogenized in a buffer (1:20  w:v) containing 0.32 M sucrose,  
10mM Tris-HCL PH 7.4, 2 mM EDTA, 10 μl/mL protease-Arrest (Protease inhibitor, 
Genotech, St. Louis, Missouri). The homogenate was centrifuged at 900 g for 10 minutes, 
and the resulting supernatant was centrifuged at 100,000 g for 1 hour. The final pellet 
which contained the plasma membrane was re-suspended in buffer (0.2 g original tissue 
in 0.5 ml) containing 50 mM Tris-HCL, 10 mM EDTA, 100 mM NaCl, and 8 mM MgCl2, 
PH 7.4.  
                   The 2 Χ loading buffer containing: 125mM Tris-HCL  PH 6.8, 20% glycerol, 
4% SDS, 0.02% bromphenol blue, 4% β-mercaptoethanol, was used to dissolve the 
suspended pellet (1:1 volume). At 95 °C for 3 minutes, membrane proteins (150 μg 
protein/lane for D1 or D2 receptor; 30ug protein/lane for β-actin) were separated using 
10% discontinuous SDS-polyacryamide gel electrophoresis (PAGE).                                                               
                   The resolved membrane proteins are transferred onto a 0.2-µm Hybond-P 
nitrocellulose sheet by semidry electroblotting for 1.0 hours and then soaked overnight in 
4% goat serum or evaporated goat’s milk at 4 °C for D1 or D2 receptor and 5% w.v-1  
nonfat milk in Tris-buffered saline (containing Tween20) for β-actin. The membranes 
were incubated at room temperature for 1 h with rabbit anti-rat D1 or D2 receptor 
polyclonal antibody (Calbiochem-Novabiochem Corporation, San Diego, CA, USA) 
using 1: 5000 dilution of the reconstituted 10mg/ml Fraction V BSA (Sigma-aldrich, 
USA) in TBS-T at room temperature for 1 h, then incubated with a biotinylated 
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secondary antibody 1: 5000 dilutions in TBS-T (Amersham Biosciences, Little Chalfont, 
UK) for 1 h, and reacted with peroxidase-conjugated streptavidin (Amersham 
Biosciences, UK) at room temperature for 1 hour. As for β-actin, after nonfat milk 
blockage the membranes were incubated at room temperature for 1 hour with mouse anti-
rat β-actin primary antibody (Santo Cruz Biotechnology, Santa Cruz, CA, USA) using 
1:5000 dilutions in TBS-T at room temperature. Then it was incubated with goat anti-
mouse secondary antibody 1: 5000 dilutions in TBS-T (Amersham Biosciences, Little 
Chalfont, UK) for 1 hour at room temperature. Specific bands were visualized by 
chemiluminescence (ECL Western Blotting Analysis System, Amersham Biosciences, 
UK), analyzed Syngene software (Cambridge, UK) and expressed as band intensity 
relative to the β-actin band (the internal standard).    
                 
 
              2.3. Results  
      2.3.1. Serum cholesterol measurement by kits from ThermoTrace 
          The serum cholesterol levels of saline treated, simvastatin treated (1, 10, 
30mg/kg/day) and pravastatin treated (30mg/kg/day) rats were shown in Fig 2.1. There is 
no significant cholesterol change observed after the simvastatin and pravastatin 
treatments for a 4-week period.  This result is consistent with previous reports 
(Kawashima et al 2003; Roglans et al 2002; Schoonjans et al 1999). In contrast, both 
simvastatin and pravastatin at 30mg/kg/day decreased serum triglyceride levels after a 4-
week treatment period (Fig 2.2). Dose dependency of the effect was also demonstrated as 
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serum triglyceride levels were reduced by 19, 29, and 49% with increasing (1, 10 or 30 
mg/kg/day) doses.  
 
              2.3.2. D1 and D2 receptor expression after statin treatment.  
                   For all samples, a single band corresponding to 359bp D1 or 410bp D2 
receptor was detected. The RT-PCR results showed that simvastatin at dosage of 
10mg/kg/day or 30mg/kg/day but not at 1mg/kg/day increased D1 receptor mRNA 
expression by about 1.8-fold in the prefrontal cortex (Fig 2.3) as well as D2 receptor 
mRNA expression by about 2.4-fold (Figure 2.4) when compared to the saline-treated 
control group. As shown in Fig 2.5 and Fig 2.6, simvastatin treatment (30mg/kg/day) 
increased D1 and D2 receptor mRNA expression by 1.6-fold and 2.2-fold, respectively, in 
the prefrontal cortex when compared to the saline-treated control group. Since only 
simvastatin at 30mg/kg/day increased triglyceride and dopamine receptor D1 and D2, one 
dosage (30mg/kg/day) of pravastatin was used. In contrast, pravastatin treatment at the 
same dose (30mg/kg/day) failed to give similar up-regulation of both D1 and D2 receptor 
mRNA expression. In addition, both simvastatin and pravastatin were without effects in 
the striatum.  Western blot analysis further confirmed that the up-regulation of D1 and D2 
receptor expression at the protein level. Simvastatin at 30mg/kg/day increased D1 (Figure 
2.7) and D2 (Figure 2.8) receptor expression by 1.3-fold and 1.5-fold, respectively in the 
prefrontal cortex when compared to the saline-treated control group. Similar results were 
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              2.4. Discussion 
                      Statins are widely used clinically to reduce serum low density lipoprotein 
(LDL) cholesterol by inhibiting the rate-limiting enzyme, hydroxymethylglutaryl-
coenzyme reductase, in cholesterol synthesis. However, according to Lea et al (1997), 
Jones et al (1998) and Stein (1998) studies, the ability of statins to reduce serum 
triglyceride concentration depends on the baseline of triglyceride levels and the potency 
and efficacy of the statins used. In the present study, the author found that both 
simvastatin and pravastatin, at 30 mg/kg/day dose, significantly decreased serum 
triglyceride level by 50% in rats after 4-week treatment, while serum cholesterol levels 
remained unchanged. Both statins thus produced a significant alteration in the lipid 
metabolism at the highest dose used. These results are consistent with previous reports 
(Roglans et al., 2002; Kawashima et al. 2003). In the study of Schoonjans et al, (1999), 
SD rats were treated with an extremely high dose of simvastatin (120 mg/kg/day) for 4 
days. The total cholesterol levels did not increase to a statistically significant level in 
sharp contrast to observation made in primates and human (Schoonjans et al, 1999). 
However their data unequivocally indicated that serum triglyceride levels decreased 
which may be attributed to a robust decrease in VLDL concentration in the serum. 
Consistently, Roglans et al (2002) also found that high dosage of both simvastatin and 
atorvastatin reduced plasma triglyceride without affecting cholesterol and 
phospholipids levels in SD rats. These authors attributed the increases in the levels of 
FA synthase (FAS) and acetyl-CoA carboxylase (ACC) to the over-expression of sterol 
regulatory element binding protein (SREBP-2) induced by the statins.  
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                     While both simvastatin and pravastatin reduced serum triglyceride to the 
same extent, only simvastatin, the lipophilic statin, up-regulated the D1 and D2 
receptors. It strongly indicated that the changes of D1 and D2 receptor expression might 
be independent of the changes in lipid metabolism.                    
                  The lack of effects for pravastatin may be attributed to its inability to cross the 
BBB readily because of its hydrophilicity. The lipophilicity, expressed as log D at pH 7.4, 
for simvastatin and pravastatin are 1.6 and -0.84, respectively (McTaggart et al., 2001). 
Consistently, Botti et al. (1991) reported that pravastatin was undetectable in the CSF of 
healthy human subjects when their serum drug concentration was >40 ng/ml. On the 
contrary, the CSF concentration of lovastatin, a lipophilic statin similar to simvastatin, 
was found to be about 11 % of that in the serum (1.3 vs 11.5 ng/ml). This, together with 
the fact that pravastatin treatment altered serum triglyceride levels to the same extent as 
simvastatin treatment which was mentioned above, strongly indicated that the lack of 
effects of pravastatin on the expression of dopaminergic receptors in the prefrontal cortex 
is due to its absence (or presence in insufficient concentration) in the brain. Thus, 
simvastatin is acting through a central mechanism to cause the observed up-regulation of 
both D1 and D2 receptors.         
                 Central dopaminergic systems are recognized to be involved in motivation, 
attention, and reward. The prefrontal cortex is an important region related to cognitive 
functions. Studying postmortem brains, de Keyser et al (1990) found that with aging, D1 
dopamine receptor densities decreased significantly. This deficit might contribute to the 
decline in cognitive abilities with age. Rinne et al (1990) also found that both D1 and D2 
receptors declined with age, and suggested that age-related degeneration of dopaminergic 
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systems contributed to the frequent occurrence of extrapyramidal symptoms and 
cognitive deficits in the elderly. Similarly, Suhara et al (1991) by using positron emission 
tomography (PET) found that D1 receptor significantly decreased with age not only in the 
frontal cortex but also in the striatum.  
                In animal studies, Rapp et al (1989) showed that prefrontal cortical dysfunction 
may lead to prominent aspects of age-dependent cognitive impairment in the monkey. 
Bachevalier et al (1991) further reported that age-related deficits were observed in aged 
monkeys on tests of spatial memory, visual habit formation, visuospatial orientation, 
visually guided reaching, motor skill learning, and reaction time.  Ricci et al (1995) also 
found that dopamine D1-like receptors in the rat cerebellar cortex underwent age-related 
decrease. Therefore, the ability of simvastatin to up-regulate central dopamine receptors 
may have potential relevance for treatment of cognitive deficits in age-related memory 
decline.  
                 The dopamine-mediated mesocorticolimbic pathways are linked to the brain 
reward and reinforcing circuits, and thus relevant to drug abuse and addiction (Bonci et 
al., 2003). Dopaminergic abnormality is also associated with the pathogenesis of 
schizophrenia (Harrison, 2000). However, it should be noted that significant adverse 
events relating to the CNS has not been reported after long-term use of statins in humans 
(Pedersen et al., 1996). Thus, it appears probable that upregulation of dopamine receptors 
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Figure 2.1  Cholesterol was measured after simvastatin and pravastatin treatment at 
different dosages for 4 weeks. Statistics were performed by General Linear Model 
multivariate analysis: Cholesterol F (4,31)=1.523, P>0.2, n=5–17 per group, total n=37, 












































  Figure 2.2   Triglyceride was measured after simvastatin and pravastatin treatment at 
different dosages for 4 weeks. Statistics were performed by General Linear Model 
multivariate analysis: Triglyceride F (4, 31) =5.259, P<0.005, n=5–17 per group, total 
n=37. * Significantly different from the saline-treated group, *P<0.02, by post hoc 
analysis with Bonferroni correction.  
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Figure  2.3  RT-PCR showed that simvastatin (sim, 10 or 30 mg/kg/day) increased D1 
receptor mRNA expression by about 1.8-fold in the prefrontal cortex when compared to 
the saline-treated control group. No changes were observed with sim treatment at 1 
mg/kg/day. Graphs showed band intensity relative to the corresponding β-actin band. 
Error bars represent SEM, n=6 per group. One-way analysis of variance (ANOVA): F (3, 
16) =85.607, P<0.001 for D1 by post hoc analysis with Bonferroni correction. Top panel 
shows typical bands of β-actin, D1 receptor in the same order (left to right) as presented 













                                
 
                        
                                                            saline    sim(1.0mg/kg)  sim(10mg/kg/day) sim (30mg/kg/day) 
  















































      
 
Figure  2.4.  RT-PCR showed that simvastatin (sim, 10 or 30 mg/kg/day) increased D2 
receptor mRNA expression by about 2.4-fold in the prefrontal cortex when compared to 
the saline-treated control group. No changes were observed with sim treatment at 1 
mg/kg/day. Graphs showed band intensity relative to the corresponding β-actin band. 
Error bars represent SEM, n=6 per group. One-way analysis of variance (ANOVA): F (3, 
16) =30.793, P<0.001 for D2 by post hoc analysis with Bonferroni correction. Top panel 
shows typical bands of β-actin, D2 receptor in the same order (left to right) as presented in 
the graph.  
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Figure 2.5.  RT-PCR showed that simvastatin (sim, 30 mg/kg/day), but not pravastatin 
(pra, 30 mg/kg/day), increased D1 receptor mRNA expression by 1.6-fold in the 
prefrontal cortex when compared to the saline-treated control group. No changes were 
observed in the striatum. Graphs showed band intensity relative to the corresponding β-
actin band. Error bars represent SEM, n=6 per group. One-way analysis of variance 
(ANOVA): F (2, 27) =6.641, P<0.005 for D1 in prefrontal cortex by post hoc analysis 
with Bonferroni correction. Top panel shows typical bands of β-actin, D1 receptor in the 
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 Figure 2.6. RT-PCR showed that simvastatin (sim, 30 mg/kg/day), but not pravastatin 
(pra, 30 mg/kg/day), increased D2 receptor mRNA expression by 2.2-fold in the 
prefrontal cortex when compared to the saline-treated control group. No changes were 
observed in the striatum. Graphs showed band intensity relative to the corresponding β-
actin band. Error bars represent SEM, n=6 per group. One-way analysis of variance 
(ANOVA): F (2, 15) =21.460, P<0.001 for D2 in prefrontal cortex by post hoc analysis 
with Bonferroni correction. Top panel shows typical bands of β-actin, D2 receptor in the 
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Figure 2.7   Simvastatin (30 mg/kg/day) increased D1 receptor expression by 1.3-fold in 
the prefrontal cortex when compared to the saline treated control group. Graphs showed 
band intensity relative to the corresponding β-actin band. Error bars represent SEM. Top 
panel shows typical bands of β-actin, D1 receptors. *P<0.05 by independent sample t-test: 
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Figure 2.8   Simvastatin (30 mg/kg/day) increased D2 receptor expression by 1.5-fold in 
the prefrontal cortex when compared to the saline treated control group. Graphs showed 
band intensity relative to the corresponding β-actin band. Error bars represent SEM. Top 
panel shows typical bands of β-actin, D2 receptors. *P<0.05 by independent sample t-test: 





















The effects of simvastatin on the expression of (e,n,i) NOS, D1 and D2 
receptors   
 
 
            3.1. Introduction:   
                It has been demonstrated in the previous chapter that simvastatin up-regulated 
the expression of dopamine receptors in prefrontal cortex; however, simvastatin is found 
to increase eNOS expression in an animal model of stroke (Endres et al. 1998). This 
gives rise to the hypothesis that the up-regulation of dopamine receptors bears a 
relationship with the up-regulation of eNOS expression after chronic treatment with 
simvastatin.   
                 It has been reported (David et al, 1997) that by injecting S-nitroso-N-acetyl-
penicillamine (SNAP), a type of nitric oxide generator, into the rat brain, D3 receptor was 
up-regulated in the striatum. More direct evidence came from a study on renal epithelial 
LLC-PK1 cells, the NOS inhibitors, L-NMMA and L-NAME, decreased the expression of 
D1 receptor. Similarly, D1 receptor was found to increase in LLC-PK1 cells treated with 
sodium nitroprusside (SNP), a NO donor, and L-arginine (L-Arg), the precursor of NO 
(Healy et al. 2000).  
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                 Dominguez at al (2004) found that extracellular dopamine increased after local 
application of glutamate in the medial preoptic area (MPOA). This increase in glutmate-
induced dopamine was inhibited by co-administration of L-NAME, indicating the 
involvement of NO. NO derived from iNOS contributed to the dopaminergic cell death 
and subsequently resulted in the dopamine decrease. In MPTP mice, chronic treatment 
with pioglitazone, a peroxisome proliferators-activated receptor (PPARγ) agonist which 
inactivates microglia and subsequently reduces expression of iNOS and the release of 
NO, increased dopamine (Dehmer et al. 2004). Consistently, dopamine was decreased in 
MPTP treated mice, secondary to NO and iNOS up-regulation (Liberatore et al 1999).  
                 Activation of dopamine receptors was found to increase the NOS. SKF R-
38393, a D1 receptor agonist, increased expression of nNOS, iNOS and eNOS in SK-N-
MC cells; this effect was blocked by D1 receptor-selective antagonist SCH23390 (Chen et 
al. 2003). Similarly, chronic treatment with the neuroleptic haloperidol in rats led to D2 
receptor up-regulation and supersensitivity and subsequently resulting in elevated levels 
of nNOS mRNA and protein expression in the striatum (Lau et al. 2003).   
          It appears that the NO and dopaminergic systems in the brain are associated 
with each other, and so it is reasonable to hypothesize that eNOS activity may regulate 
the central dopaminergic systems. To date, there is little knowledge with respect to NOS- 
dopamine interaction. Since statins may simultaneously up-regulate eNOS and D1 and D2 
receptors, the objective of this study was to investigate a possible cause-and-effect 





                       3.2. Methods 
                       3.2.1. Animal and statins pretreatment  
                          SD rats were given saline or simvastatin orally at dosage of 10mg/kg/day 
or pravastatin at dosage of 30mg/kg/day for 4 weeks. eNOS knock-out mice, C57 BL 
mice were treated with simvastatin 10mg/kg/day orally for 4 weeks and another group of 
C57 BL mice were given saline treatment as the control group.  
                    SD rats were divided into 8 groups: 0.9% saline administrated orally group, 
0.9% saline administrated orally combined with intraperitoneal injection of SCH23390 
(0.2mg/kg/day), 0.9% saline administrated orally combined with intraperitoneal injection 
of Haloperidol (0.1mg/kg/day), 0.9% saline administrated orally combined with 
intraperitoneal injection of SCH23390 (0.2mg/kg/day)+ Haloperidol (0.1mg/kg/day), 
simvastatin (10mg/kg/day) orally administrated group, simvastatin (10mg/kg/day) orally 
administrated group combined with intraperitoneal injection of SCH23390 
(0.2mg/kg/day), simvastatin (10mg/kg/day) orally administrated group combined with 
intraperitoneal injection of Haloperidol (0.1mg/kg/day), simvastatin (10mg/kg/day) orally 
administrated group combined with intraperitoneal injection of SCH23390 
(0.2mg/kg/day) + Haloperidol (0.1mg/kg/day). All groups above were given different 
treatments for 4 weeks.  
 
 
                       3.2.2. Preparation of RNA from prefrontal cortices and striata of SD 
rats or mice.  
                          RNA preparation procedure followed the method described in chapter 3.  
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                       3.2.3. Reverse transcription-ploymerase chain reaction (RT-PCR) for 
(e, n, i) NOS (rats), D1 and D2 dopamine receptor (mice) expression.  
                          RT-PCR procedure followed the method described in chapter 3. Sense 
and antisense primers for eNOS, nNOS, iNOS (rats), and D1/D2 dopamine receptors 
(mice) are shown following.  
eNOS (rat) sense 5’-TGCACCCTTCCGGGGATTCT-3’, 
 
eNOS antisense 5’-GGATCCCTGGAAAAGGCGGT-3’ (189bp)  
 
 nNOS (rat) sense 5’-GGC ACT GGC ATC GCA CCC TT-3’,  
 
 nNOS  antisense 5’-CTT TGG CCT GTC CGG TTC CC-3’ (213 bp).  
 
iNOS (rat) sense 5’-AGC ATC ACC CCT GTG TTC CAC CC-3’,  
 
 iNOS  antisense 5’-TGG GGC AGT CTC CAT TGC CA-3’ (388bp).  
 
D1  sense (mice) 5'-CTC ATA AGC TTT TAC CAT CCC CG-3’  
D1   antisense 5'-CCC TCT CCA AAG CTG AGA TG-3’ (103bp), 
D2 sense (mice) 5'-AAC CTG TCC TGG TAC GAT GAC GAT-3’ 
D2 antisense 5’-GCA CAT CAT GAC ATC CAG AGT GAC-3’ (342bp) 
PCR denaturing, annealing, and extension reactions proceeded respectively at 95°C for 
30 sec, 62°C for 30 sec, and 72°C for 30 sec (rat eNOS 35 cycles. De Gennaro Colonna 
et al 2002);  94°C for 1 min, 66°C for 1 min, and 72°C for 1 min (rat nNOS 35 cycles. 
Wu, F et al 1999);  94°C for 1 min, 64°C for 1 min, and 72°C for 1 min (rat iNOS 35 
cycles. Wu, F et al 1999); 94°C for 2 min, 55°C for 2 min, and 72°C for 3 min (C57BL 
mice D1DA 35 cycles, T. Suzuki et al 2003);  93°C for 1.5 min, 61°C for 1.5 min, and 




              3.2.4. Quantification of PCR products 
                         PCR quantification procedure followed the method described in chapter 2.  
 
             3.2.5. Western Blot analysis for eNOS protein  
                  Western blot was used to measure the eNOS protein’s change after the 
simvastatin treated.   
                  Extraction of protein procedure followed that described in chapter 2. 
 After soaked in 5% w.v-1 nonfat milk in Tris-buffered saline containing Tween20 at 4 
°C, the membranes were incubated at room temperature for 1 h with rabbit anti-rat eNOS 
polyclonal, rabbit anti-mice eNOS, or β-actin antibody (Santa Cruz Biotechnology, USA) 
using 1:800, 1:250, and 1:5000 dilutions in TBS-T at room temperature for 1 h 
respectively. Then membranes were incubated with goat anti-mouse secondary antibody 
1: 5000 dilution in TBS-T (Amersham Biosciences, UK) for 1 hour at room. Specific 
bands were visualized as that of chapter 2.  
 
 
                    3.3. Results  
                         3.3.1. NOS mRNA expression measured by RT-PCR in the prefrontal 
cortex and striatum after simvastatin treatment.               
                      Figure 3.1 showed that simvastatin treatment at 10mg/kg/day increased 
eNOS mRNA expression by 2-fold in the prefrontal cortex when compared to the saline-
treated control group. In contrast, pravastatin treatment at 30mg/kg/day was found to be 
ineffective. Both simvastatin and pravastatin treatments showed no effects in the 
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striatum.  Since maximum up-regulation of dopamine receptors was observed at 
10mg/kg/day dose of simvastatin treatment, this dose was used for the determination of 
eNOS, nNOS, and iNOS expression. Compared to saline-treated control group, however, 
the same dose of simvastatin (10mg/kg/day) has no effect on the expression of nNOS or 
iNOS (Figure 3.2). The increased expression of eNOS after simvastatin was confirmed by 
Western blot analysis (Figure 3.3). eNOS expression was increased 1.8-fold in the 
prefrontal cortex when compared to the saline-treated control group.   
 
 
                     3.3.2. D1 and D2 dopamine receptor mRNA expression measured by RT-
PCR in the prefrontal cortex of eNOS knockout mice.    
                    eNOS knock-out mice were confirmed  not to express eNOS by Western blot 
analysis (Figure 3.4). Simvastatin treatment (10mg/kg/day) increased D1 dopamine 
receptor mRNA expression by 1.7-fold in the prefrontal cortex of both C57 BL mice and 
eNOS knock-out mice (Figure 3.5). Similarly, Figure 3.6 showed that D2 dopamine 
receptor mRNA expression was increased by 2-fold.  
 
 
                    3.3.3. eNOS mRNA expression in the prefrontal cortex of SD rats after 
dopamine receptor D1 and D2 receptors blockade.   
                    As described earlier, simvastatin treatment increased eNOS expression by 
2.3 fold in the saline control group. However, coadministration with D1 antagonist, 
Chapter 3 
 63
SCH23390 (SCH 0.2mg/kg/day), D2 antagonist, haloperidol (HAL 0.1mg/kg/day) or both, 
did not significantly alter the effect of simvastatin on eNOS expression.  
 
             3.4. Discussion 
      Up-regulation of eNOS expression in vascular tissues by statins has been 
reported in several species (Kano et al., 1999; Yamada et al., 2000; Mital et al., 2000; 
Wassmann et al., 2001). Only Endres et al. (1998) demonstrated simultaneous up-
regulation of eNOS in the aorta and brain (cerebral hemisphere) of 129/SV mice treated 
for 14 days with simvastatin (20 mg/kg/day). The present data extended this finding by 
showing up-regulation of eNOS expression in the rat brain and regional differences 
between the prefrontal cortex and striatum. Endres et al. (1998) further demonstrated that 
the neuroprotective effects of simvastatin against focal cerebral ischemia observed in 
these mice were completely absent in eNOS-knock out mice, indicating that increased 
eNOS activity is the underlying mechanism of the neuroprotection. The present 
observation that after 4 weeks simvastatin treatment nNOS and iNOS were not up-
regulated together with eNOS is consistent with the above conclusion.  
   In contrast to simvastatin, pravastatin did not increase the expression of eNOS, 
as well as the dopamine receptors. This may be attributed to the hydrophilicity of 
pravastatin, which is unable to cross the blood-brain barrier readily.  Rosuvastatin (up to 
20 mg/kg/day) was also reported to provide neuroprotection similar to those of 
simvastatin and atorvastatin while up-regulating eNOS in mice (Laufs et al., 2002). 
However, in the above study, up-regulation of eNOS in the brain was presumed based on 
the up-regulation of eNOS in the aorta. Since rosuvastatin has low lipophilicity (log D at 
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pH 7.4 is -0.33, McTaggart et al., 2001), it is uncertain whether eNOS was indeed up-
regulated in the brain by rosuvastatin in view of the present finding with pravastatin. 
      This chapter reported that concomitant to up-regulation of D1 and D2 receptor 
expression, eNOS expression was increased in the prefrontal cortex. It has been reported 
that inhibition of NO synthesis by L-NAME reduced significantly haloperidol-induced 
supersensitivity resulting from dopamine (D2) receptor up-regulation (Pudiak and 
Bozarth, 1997). Similarly, rats chronically treated with haloperidol showed elevated 
nNOS expression (Lau et al., 2003). Chemical hypoxia-induced increase in D1A receptor 
mRNA expression in renal epithelial cells was also blocked by L-NAME (Healy et al., 
2000). These prompted the speculation that the up-regulation of D1 and D2 receptors is 
secondary to that of eNOS in the prefrontal cortex after simvastatin treatment. The facts 
that D1 and D2 receptor expression were up-regulated in eNOS knockout mice after 
chronic simvastatin treatment, and the lack of effect for D1 and D2 receptor blockade 
during simvastatin treatment on eNOS up-regulation demonstrated that eNOS and 
dopamine receptor up-regulations occurred independently from each other.  
       Interestingly, contrasting results have also been reported. Chen et al,(2003) 
found that direct activation of D1 dopamine receptor with SKF R-38393, a full D1 
dopamine receptor agonist, increased expression of iNOS and eNOS in SK-N-MC cell 
culture through immunoblot analysis, and these increased expressions were blocked by 
SCH 23390, the full D1 dopamine receptor antagonist.  It is possible that the observed 
effects of SKF R-38393 on eNOS expression is a pharmacological one, while under 
physiological condition, D1 dopamine receptor activity does not normally influence the 
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Figure 3.1.     RT-PCR showed that simvastatin (sim, 10 mg/kg/day), but not pravastatin 
(pra, 30 mg/kg/day), increased eNOS mRNA expression by 2.06-fold in the prefrontal 
cortex when compared to the saline-treated control group. No changes were observed in 
the striatum. Graphs showed band intensity relative to the corresponding β-actin band. 
Error bars represent SEM. One-way analysis of variance (ANOVA): F (5,36)=11.15, 
P<0.001, n=7 per group for eNOS in prefrontal cortex by post hoc analysis with 
Bonferroni correction. Top panel shows typical bands of β-actin, eNOS in the same order 
(left to right) as presented in the graph.  
 
       β-actin 
     eNOS  
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 Figure 3.2.    RT-PCR showed that simvastatin (sim, 10 mg/kg/day) increased eNOS 
mRNA expression by 2.2-fold in the prefrontal cortex when compared to the saline-
treated control (C) group. No changes in expression were observed for nNOS and iNOS. 
Graphs showed band intensity relative to the corresponding β-actin band. Error bars 
represent SEM. Top panel shows typical bands of β-actin, eNOS, nNOS and iNOS as 
indicated.  *P<0.001 by independent sample t-test: t=4.460 for eNOS, n=7 per group.  
 
        
















           
 
Figure 3.3   Simvastatin (10 mg/kg/day) increased eNOS protein expression by 1.8-fold 
in the prefrontal cortex of SD rats when compared to the saline-treated control group. 
Graphs showed band intensity relative to the corresponding β-actin band. Error bars 
represent SEM. Top panel shows typical bands of β-actin and eNOS. *P<0.001 by 
independent sample t-test: t=19.694, n=6 per group.  
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  Figure 3.4.    Western blot analysis showed that eNOS protein is obviously observed 
in C57 BL mice but it can’t be detected in eNOS knockout mice, which demonstrated that 
the eNOS has been knocked out, and can be used in our next experiment.  
                  


























































Figure 3.5    RT-PCR results showed that simvastatin (sim, 10 mg/kg/day) increased D1 
receptor mRNA expression by 1.71-fold and 1.72-fold in the prefrontal cortex in C57BL 
(eNOS knockout background mice) and eNOS knockout mice, respectively, when 
compared to the saline-treated control group (C57 BL mice). Graphs showed band 
intensity relative to the corresponding β-actin band. Error bars represent SEM. One-way 
analysis of variance (ANOVA): F (2,15)=79.019, *P<0.001, **P<0.001, n=6, for D1 in 
prefrontal cortex by post hoc analysis with Bonferroni correction. Top panel shows 
typical bands of β-actin, D1 receptor in the same order (left to right) as presented in the 
graph.  
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Figure 3.6.  RT-PCR results showed that simvastatin (sim, 10 mg/kg/day) increased D2 
receptor mRNA expression by 2.05-fold and 2.09-fold in the prefrontal cortex in C57BL 
(eNOS knockout background mice) and eNOS knockout mice, respectively, when 
compared to the saline-treated control group (C57 BL mice). Graphs showed band 
intensity relative to the corresponding β-actin band. Error bars represent SEM. One-way 
analysis of variance (ANOVA): F (2,15)=175.478, *P<0.001, **P<0.001, n=6, for D2 in 
prefrontal cortex by post hoc analysis with Bonferroni correction. Top panel shows 
typical bands of β-actin, D2 receptor in the same order (left to right) as presented in the 
graph.   
 
β-actin 






























                                  Sal         Sim         SCH       SCH+Sim   Hal    Hal+Sim   SCH+Hal   SCH+Hal+Sim  
 





















* * * *
SCH HALSAL SCH+HAL
 
    
Figure 3.7.   RT-PCR result showed that when compared to the saline-treated groups 
orally, simvastatin administration (10 mg/kg/day) increased eNOS mRNA expression by 
2.30-fold, 2.39-fold, 2.16-fold, and 2.13-fold in the injection of saline (SAL), SCH23390 
(SCH 0.2mg/kg/day), haloperidol (HAL 0.1mg/kg/day), and SCH23390+haloperidol 
(SCH+HAL) treated groups, respectively. Graphs showed band intensity relative to the 
corresponding β-actin band. Error bars represent SEM. One-way analysis of variance 
(ANOVA): F (7, 40) =43.712, n=6 per group, *P<0.001 against saline-treated groups by 
post hoc analysis with Bonferroni correction. In four saline-treated groups, no change of 
eNOS expression was found. Top panel shows typical bands of β-actin, eNOS in the 
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Functional study of D1 and D2 by measuring cAMP levels in the 
synaptomsomes of the prefrontal cortex in SD rats after simvastatin 
treatment  
 
                 
          4.1. Introduction:  
                    In the study of function for dopamine receptors, cAMP is usually measured 
in synaptosomes of the tissue in the presence of dopamine receptor agonist and /or 
antagonist. Among all the D1 and D2 receptor agonists and antagonists, chloro-APB and 
quinpirole hydrochloride are often used as agonists for D1 and D2 receptors respectively, 
while SCH-23390 and haloperidol or sulpiride are used as D1 and D2 receptor antagonists 
respectively.  
                     Iorio et al (1983) found that SCH 23390 acted as specific D1-receptor 
antagonist and showed blockade of dopamine-stimulated adenylate cyclase activity and 
postulated that SCH 23390 is a selective D1-receptor antagonist. Later, Cross et al (1983) 
obtained similar findings showing that SCH 23390 displaced with high potency [3H]-
piflutixol binding to calf striatal dopamine D1 receptors. In contrast, SCH 23390 was only 
a weak displacer of H-spiperone binding to dopamine D2 receptor (Cross et al, 1983). 
Chloro-APB hydrobromide (SKF-82958) stimulated endothelial cAMP formation in a 
dose-dependent manner, which was attenuated by (+/-) SCH-23390, also in a dose-
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dependent manner (Bacic et al, 1991). Domino et al, (1993) studied a series of dopamine 
agonists on circling behavior in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-
induced hemiparkinsonian monkeys, and found that chloro-APB hydrobromide (SKF-
82958) was a relatively effective D1 receptor agonist compared with other D1 receptor 
agonists.  
                In contrast to D1 receptor, D2 receptor is negatively linked to adenylyl cyclase.  
Stoof et al. (1981) demonstrated that quinpirole dihydrochloride (LY 141865), 
diminished the magnitude of the SKF 38393-induced efflux of cAMP (Stoof et al. 1982). 
Kelly et al, (1987) also showed that the enhancement of cAMP accumulation due to the 
selective D1 agonist SKF 38393 (2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-
benzazepine) in striatal slices was attenuated by quinpirole. This effect for D2 receptor 
agonists on the effects of D1 receptor agonists on cAMP efflux occurred in a non-
competitive manner (Stoof et al, 1981).  
               As reported in the previous chapters, simvastatin treatment for 4 weeks up-
regulated the expression of dopamine receptors D1 and D2. In this chapter, the functional 
changes of D1 and D2 receptors in synaptosomes of prefrontal cortex were explored by 
studying the effects of selective agonist and antagonists on cAMP levels.  
 
 
                    4.2. Methods  
                       4.2.1. Animal and statins pretreatment  
                          SD rats were given saline or simvastatin orally at dosage of 10mg/kg/day 
for 4 weeks for cAMP measurement experiment.  
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                      4.2.2. Different reagents and drugs preparation  
                       Ice-cold 0.32 M sucrose (10w/v) 
                       Direct cAMP enzyme immunoassay kit (Sigma CA-200)  
                       Phosphate-buffered krebs medium (Tissari et al 1993)  containing (in mM) 
NaCL 128, Na2HPO4 10, KCL 4.7, CaCL2 2.5, MgSO4 1.2, Glucose 11, ascorbic acid 
1.1, and Na2EDTA 0.16 at PH 7.0 was aerated with 95% O2 and 5% CO2 for 1 hour 
before cAMP measurement.  
                        Drugs: D1 antagonist: SCH-23390 hydrochloride (25µM)   
                                    D1 agonist: 6-chloro-7,8-dihydroxy-3- 
                                         allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine                   
hydrobromide or chloro-APB (5µM) 
                                     D2 agonist: quinpirole hydrochloride (5µM) 
                        All drugs and chemicals were of analytical grade and obtained from 
Sigma-Aldrich (St Louis, Missouri).  
 
                     4.2.3. Preparation of rat prefrontal cortex synaptosomal membranes  
                        Male Sprague-Dawley rats (280—300g) after the simvastatin treatment at 
dosage of 10mg/kg/day for 4 weeks were killed followed by decapitation. The brains 
were removed and the prefrontal cortices were rapidly dissected over ice and 
homogenized in 10 volumes of 0.32 M sucrose, pH 7.2, in a 0.25mm clearance Teflon-
glass homogenizer. The homogenate was centrifuged at 1000×g for 15 min to remove 
nuclei and unbroken cells. The pellet (P1) was discarded and the supernatant was 
centrifuged at 20,000×g for 20 mins to sediment the P2 pellet. This P2 pellet was 
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resuspended in 10 volumes of 0.32 M sucrose (10 w/v).After killing the animals until the 
start of incubation at 37ºC, all procedures were strictly performed at temperature of 2-4ºC 
with the tubes containing the tissue being immersed in ice until use within 2 hours 
(Haycock and Patrick 1981; Tissari  et al 1993).  
 
 
                    4.2.4. Synaptosome cAMP measurement after D1 and D2 antagonist or 
agonist treatment.  
                      After preparation of synaptosome and Krebs medium, synaptosomal 
preparation (0.1 ml) was added to phosphate-buffered Krebs medium containing NaCl 
(128 mM), Na2HPO4 (10), KCl (4.7), CaCl2 (2.5), MgSO4 (1.2), D-Glucose (11), ascorbic 
acid (1.1), and Na2EDTA (0.16) at pH 7.0, aerated with 95% O2 and 5% CO2 for 1 h. 
SCH-23390 hydrochloride (25 uM) was also added if appropriate. The mixture was 
warmed at 37ºC for 10 min. Agonist drugs (6-chloro-7,8-dihydroxy-3- 
allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide or chloro-APB, 
quinpirole hydrochloride, or both at 5 µM each) were then added and incubation 
continued for another 25 min. The final incubation volume was 1 ml. After incubation, 
tissue was recovered by centrifugation (20,000×g for 20 min, 4ºC) and protein contents 
were determined by the Bio-Rad Protein Assay kit with the UV 1601 machine.  cAMP 
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                  4.3. Results for cAMP measurement  
                       Figure 4.1 shows that cAMP level in synaptosomes from saline-treated and 
simvastatin-treated group were about 20 pmol/mg protein. D2 receptor activation by 
quinpirole hydrochloride (5 µM) did not significantly alter the synaptosomal cAMP 
levels of either group. In contrast, D1 receptor activation by chloro-ABP (5 µM) 
significantly increased cAMP levels by 88% in synaptosomes from control rats, and 
285% in synaptosomes from simvastatin-treated rats. These increases were attenuated by 
the D1 antagonist SCH-23390 (25 µM). Furthermore, chloro-ABP induced increases were 
also abolished by quinpirole hydrochloride (5 µM).  
 
 
4.4. Discussion  
Dopamine receptors can be divided into two subcategories as D1 and D2 
receptors. Kebabian et al,(1979) indicated that D1 receptor was defined as being inducing 
a Gs protein increase in the synthesis and the stimulation of adenylyl cyclase activity 
resulting in intracellular concentration of cAMP increase that may initiate a complex 
group of intracellular events (Greengard et al., 1998). In contrast, Vallar et al, (1989) 
indicated that when D2 receptor, a protein linked to Gi-coupled receptor and inducing its 
increase, was activated, various responses would occur including inhibition of 
phosphatidylinositol turn-over, increase in K+ channel activity, inhibition of Ca2+ 
mobilization, and inhibition of adenylyl cyclase activity so as leading to cAMP decrease.   
                Dopamine receptor function was studied by measuring cAMP levels in 
synaptosomes from rats pretreated with simvastatin to ascertain increased dopaminergic 
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receptor function after up-regulation of receptor expression. The basal level of cAMP in 
the synaptosomal preparation was found to be about 20 pmol/mg protein, consistent with 
previously reported values (Heuschneider and Schwartz, 1989). The observation that 
activation of D2 receptors by quinpirole did not cause any significant reduction in cAMP 
levels indicates a very slow cAMP turnover rate in the synaptosomal preparations. On the 
other hand, activation of D1 receptors raised cAMP levels by 88% in synaptosomes 
prepared from untreated control rats. In synaptosomes prepared from simvastatin-treated 
rats, D1 receptor activation caused a markedly enhanced effect (a 285% increase). Thus, 
the observed 1.3 fold increase by simvastatin in D1 receptor protein expression (Chapter 2) 
was translated to a 2.6 fold increase in function based on the chloro-APB-induced 
increase in cAMP levels (Figure 4.1). Chloro-APB-mediated increase in cAMP levels 
was largely attenuated by SCH-23390 at 5 times the concentration of the agonist, further 
confirming the involvement of D1 receptors. Moreover, D2 receptor function was 
demonstrated by the complete abolition of the D1-mediated increase in cAMP. It suggests 
that activation of D2 dopamine receptor using quinpirole was expected to inhibit adenylyl 
cyclase via Gi-dependent signaling and to thereby blunt the stimulatory action of the D1 
dopamine receptor agonist chloro-APB. Kudlacek et al, (2003) found that in vitro 
stimulation of the D2 dopamine receptor by quinpirole invariable caused inhibition of A2A 
–receptor-induced cAMP accumulation and also inhibited the forskolin-stimulated cAMP 
formation.  
                   It is interesting to note that simultaneous activation of D1 and D2 receptors in 
these synaptosomes prepared from both control and simvastatin-treated rat prefrontal 
cortex resulted in a zero net change in cAMP levels. However, this may not reflect the in 
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vivo situation given the differential potency of dopamine at the D1 and D2 receptors and 
differential distribution of these receptors in pre- and postsynaptic locations.                                   
                   In conclusion, simvastatin upregulates the expression of D1 and D2 receptors 
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                                                                      Figure  
 
 
   
Figure 4.1 Synaptosomal preparations were obtained from the prefrontal cortex of rats 
treated with saline or simvastatin (10 mg kg-1day-1) and then incubated with various drugs 
as indicated. cAMP levels were determined as described in text. Sal=saline, 
Quin=quinpirole (5 (M), CAPB=chloro-APB (5 (M), SCH=SCH-23390 (25 (M), n=4–14 
per group, total n=65. Statistical analysis was performed using General Linear Model 
multivariate analysis: pretreatment (Control vs simvastatin-treated rats): F(1,55)=22.202, 
P<0.001; drug treatment: F(4,55)=23.502, P<0.001; interaction: F(4,55)=5.234, P<0.002. 
*P<0.001 against Sal, Quin and CAPB/Quin and **P<0.05 against Sal, Quin and CAPB 
by post hoc analysis with Bonferroni correction. 
 
 








Dopamine content and its re-uptake in the prefrontal cortex and 
striatum of SD rats after simvastatin treatment  
 
 
          5.1. Introduction:                    
                  Dopamine is derived from the amino acid L-tyrosine, which is hydroxylated 
by tyrosine hydroxylase to L-dopa and subsequently decarboxylated by L-aromatic 
amino acid decarboxylase to form dopamine. Once released into the synaptic cleft from 
the nerve terminal, dopamine is rapidly cleared by a re-uptake process (Gonon 1997; 
Sesack et al 2003).    
                 As a neurotransmitter, dopamine controls a variety of functions including 
locomotor activity, cognition, emotion, positive reinforcement, food intake, and 
endocrine regulation. Changes in dopaminergic functions in the brain have important 
clinical implication. The loss of dopamine in the basal ganglia is associated PD (Hoehn 
et al 1967; Hornykiewicz  et al 1986) with the greatest reduction of tissue content of 
dopamine in the putamen (Kish et al 1988, 1992). The dopamine content in the caudate 
nucleus was found to decrease not only in PD but also in aged human (Carlsson et al 
1976), which correlate with age-related reduction in motor activity.  
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                Dopamine dysfunction in the brain is not only related to motor activity but 
also to psychological disorders. Suzuki et al, (2002) found in methamphetamine-
sensitized rats, which was used as an animal model of hypersensitivity and vulnerability 
to emotional stress related to stimulant-induced psychosis and schizophrenia, and 
conditioned fear stress produced an obvious increase of dopamine release in the 
amygdala. Konstandi et al, (2000) also found that stress decreased dopamine level in the 
hypothalamus but a remarkable increase in the amygdale in mice. Moreover, stress 
caused a decrease in dopamine levels in the rat striatum but an increase in the locus 
coeruleus of in mice (Konstandi et al, 2000). Increase in dopamine content was also 
reported in schizophrenia patients (Breier et al, 1997).  
                  In previous chapters, it has been demonstrated that chronic treatment of 
simvastatin upregulates dopamine receptors in the prefrontal cortex indicating a 
potential of increased dopaminergic functions even if dopamine release remains 
unaltered. It is therefore logical to study the dopamine content and re-uptake in these 
regions after simvastatin treatment.  
 
 
                    5.2. Methods 
                    5.2.1. Dopamine transmission measurement by HPLC-MS/MS 
                    5.2.1.1. Animal and statins pretreatment  
                          SD rats were given saline or simvastatin orally at dosage of 10mg/kg/day 
for 4 weeks for following experiment, which was demonstrated in chapter 2.  
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                     5.2.1.2. Reagents and standards  
                          Dopamine and internal standard were purchased from Sigma. HPLC 
grade methanol and acetonitrle were purchased from Merck Darmstadt, Germany. Milli 
Q water was used for mobile phase preparation.  
 
                     5.2.1.3. HPLC-MS instrumentation  
                     The high-performance liquid chromatographic system consisted of an 
Agilent 1100 Binary pump quipped with an Agilent 1100 autosampler injector with 100 
loop and 1100 column oven set at 23°C (Agilent Technologies, Germany). 
Chromatographic separation will be optimized according to different compounds 
quantified. HPLC-MS analysis was performed using an API 2000 triple-quandrupole   
mass spectrometer (Applied Biosystems, MDS SCIEX, Ontario, Canada). The instrument 
conditions will be optimized according to different compounds quantified.  
 
                      5.2.1.4. Sampling of prefrontal cortex and striatum 
                          Rats were killed with CO2 and brains were dissected. The prefrontal 
cortices and striata were isolated and immersed immediately in liquid nitrogen and stored 
at -80 0C till for HPLC analysis. The prefrontal cortex samples were homogenized after 
adding 0.1 N HClO4 solutions in the ratio of 1 ml per 0.1 g brain tissues into the plastic 
tubes. However, the striatum tissues were processed the same way but in the ratio of 1 ml 
of 0.1 N HClO4 solutions per 0.05 g tissue. The tissues were homogenized for 30 seconds 
and the resulting homogenates were centrifuged for 5 min at 15000 g.  Collect the 500-µl 
supernatant for quantification of dopamine.  
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                  5.2.1.5. Solid phase extraction 
                         The supernatants were spiked with 10 µl of 1,1,2,2-D4 dopamine 
hydrochloride solution used as internal standard and alkalized using 600 µl of glycine 
buffer solution (pH=11.5). The solid-phase extraction (SPE) was performed using Bond 
Elut-PBA column (1 ml). The columns were conditioned subsequently with 1 ml of 
methanol, and 1 ml of 10 mM ammonium acetate, adjusted to pH 8.0 with ammonium 
solution. The alkalized supernatants were loaded and then washed with 1 ml of 10 mM 
ammonium acetate and followed by 1 ml of Milli-Q water. The columns were dried under 
vacuum for 5 seconds. The columns were eluted with 200 µl of trifluoroacetic acid (0.1) 
for three times. The first 200 µl of elute was disposed and the following second and third 
200 µl of elute were collected and combined in 1.7 ml centrifuge tubes. The tubes were 
centrifuged at 5,000 g for 5 minutes. 100 µl of elute supernatant was transferred into 
injection vial (250 µl) for analysis. 10 µl of elute supernatant was injected into the 
HPLC-MS/MS system.  
 
 
                  5.2.2. Dopamine re-uptake experiment  
                     5.2.2.1. Animal and statin pretreatment  
                        SD rats were given saline or simvastatin orally at dosage of 10mg/kg/day 
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                    5.2.2.2. Synaptosome preparation 
                  Male Sprague-Dawley rats (280—300g) were decapitated, and the brains were 
removed and placed onto an ice old plate for dissection. The prefrontal cortices and 
striata were then homogenized in 40 volumes of ice-old 0.32 M sucrose solution, pH 7.4, 
in a 0.25mm clearance Teflon-glass homogenizer. Homogenates were then centrifuged at 
1000×g for 10 min at 4ºC to remove nuclei and unbroken cells. The pellet (P1) was 
discarded and the supernatant was centrifuged at 20,000×g for 25 min to sediment the P2 
pellet. This P2 pellet was resuspended in 20 volumes or 30 volumes of phosphate-
buffered Krebs medium (per original wet tissue weight) for prefrontal cortex and striatum 
respectively. After killing the animals until the start of incubation at 37ºC, all procedures 
were performed at 4ºC (Haycock and Patrick 1981; Ng et al, 1999).  
 
 
                     5.2.2.3. Dopamine re-uptake measurement  
                         DA uptake was assayed as previously described (Ng et al, 1999) with a 
little modification. This synaptosomal membrane was incubated with phosphate-buffered 
Krebs medium at 37 ºC for 5 min pre-incubation before the addition of [3H] DA (0.5 µCi, 
0.1 ml, final concentration of 1 µM). 10 min later, uptake was stopped by rapid filtration 
under vacuum through a Whatman GF/C cellulose nitrate filters (0.25 µm pore size) 
which were then washed twice with 3 ml ice-old saline. The filters were placed in liquid 
scintillation vials containing 7.5 ml of Picofluor (Amersham), and radioactivity retained 
on the filters were determined by liquid scintillation spectrometry (Beckman LS 3801; 
Beckman Instruments, Fullerton. CA). Nonspecific uptake was determined in the 
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presence of 10 µM nomifensine in the essay buffer (Steffens M et al., 2004). Specific 
uptake was defined as total uptake minus the nonspecific uptake.      
 
 
                    5.3. Results 
                       Fig 5.1 in the calibration curve obtained at different concentration of 
dopamine. Fig 5.2 shows the multiple reaction monitoring (MRM) chromatogram of 
dopamine and internal standard (1,1,2,2-D4-dopamine).  
                     After 4 weeks treatment with simvastatin, dopamine level in the prefrontal 
cortex decreased to 28% of control value (Fig 5.3). On the contrary, dopamine levels in 
the striatum after simvastatin treatment increased by 2-fold compared to control value 
(Fig 5.3). Dopamine re-uptake remained unchanged in both prefrontal cortex and striatum 
(Fig 5.4).   
 
                                          
                5.4. Discussion 
                     The conversion of tyrosine to L-DOPA and to dopamine occures in the 
cytosol. Dopamine is then taken up into the storage vesicles via the Vesicular Monamine 
Transporter (VMAT-2). The vesicles release their content, through Ca-activated fusion 
with the neuronal membrane (Westerink et al, 1998). Generally speaking, the release of 
dopamine from axon terminals is thought to be impulse dependent (Nieoullon et al, 1977; 
Santiago et al, 1991). While dendritic dopamine release is also dependent on fast sodium 
channel conductance (Robertson et al., 1991). The main mechanism for clearance of 
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released dopamine is by the dopamine transporter (DAT), a membrane transporter that 
clear dopamine from the synaptic cleft (Jones et al, 1998; Giros et al, 1996; Amara et al, 
1993).   
                 In the present study, whole tissue was lysed in 0.1 N perchloric acid and the 
supernatant was obtained for dopamine measurement by HPLC. Thus, the dopamine 
levels measured reflect the combined intracellular and extracellular dopamine levels 
(Lotharius  et al, 2000). Decreased tissue dopamine together with an unchanged 
dopamine uptake may reflect a fall in dopaminergic activities. Since this occurred at a 
time when dopamine receptors were up-regulated, it raises the possibility that the 
receptor up-regulation was due to at least in rat, reduced dopaminergic input on the 
postsynaptic receptors.  
                  Reduced tissue dopamine levels can occur under various conditions. Hutson et 
al, (1997) showed that L-701,324, a novel full antagonist at the glycine/NMDA receptor, 
decreased the dopamine concentration in the medial prefrontal cortex. (+)-7-hydroxy-2-
(N,N-di-n-propylamino) tetralin ((+)-7-OH-DPAT), the dopamine D2/3 receptor agonist at 
a low dose (30nmol/kg, sc), was found to reduce dopamine in the medial prefrontal 
cortex (Westerink et al, 1998).  
                   In addition, Dazzi et al, (2004) found that long term (3 weeks) administration 
of olanzapine (1mg/kg/day, IP) and clozapine (10mg/kg/day, IP) inhibited the foot shock 
stress induced dopamine output in prefrontal cortex of SD rats, but acute administration 
of olanzapine and clozapine did not show such an effect.  However, high doses of 
clozapine caused a marked increase in dopamine release in the prefrontal cortex possibly 
by activating 5-HT1A receptor. On the other hand, acute administration of diazepam (2.5-
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10mg/kg, IP) and midazolam (2.5-10mg/kg, IP) were found to significantly decreased 
dopamine release in the prefrontal cortex (Dazzi et al, 1995).   
                   Conversely, the present author found that 4 weeks treatment with simvastatin 
increased the dopamine tissue level in the striatum with no significant change of the 
dopamine re-uptake found.  This suggests increased dopaminergic input on the 
postsynaptic cells in the striatum. However, no upregulation of dopamine receptors was 
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Figure 5.1.   Calibration curve for quantification of dopamine in rat brain tissue 
























Figure 5.2.    MRM chromatogram for dopamine (upper) for rat brain and and1,1,2,2,-



































                                                                                









Figure 5.3.  Dopamine tissue level in the prefrontal cortex and striatum was measured 
by HPCL-MS after simvastatin administration for 4 weeks orally. Data are means ± 
S.E.M of dopamine tissue level between control (open bar) and simvastatin treatment 
(solid bar), *P<0.001 by independent sample t-test: t= 5.932, n=7 for prefrontal cortex; 
**P<0.001  t= 5.581 n=7 for striatum, indicating statistical difference between control 
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Figure 5.4.   Dopamine re-uptake in the prefrontal cortex and striatum was measured 
after simvastatin administration for 4 weeks orally. Data are means ± S.E.M of dopamine 
re-uptake level between control (open bar) and simvastatin treatment (solid bar), P=0.765 
by independent sample t-test: t= 0.307 n=6 for prefrontal cortex; P=0.214 by independent 
sample t-test: t= 1.35 n=5 for striatum, indicating no statistical difference between control 
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Effects of Simvastatin on dopamine D1 and D2 receptor expressions in 
the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats  
 
          
             6.1. Introduction:            
                      Statins, inhibitors of the rate-limiting enzyme hydroxymethylglutaryl-
coenzyme A reductase in cholesterol synthesis, are used widely clinically to reduce 
serum cholesterol and triglyceride levels. Recent evidence shows that these drugs may 
reduce the risk of ischemic heart or coronary artery disease events and stroke (Cannon et 
al, 2004; El-Jack et al, 2003; Law et al, 2003; Topol et al, 2004). They are also being 
recognized to have potential application in peripheral arterial disease, end-stage renal 
disease, diabetes mellitus and Alzheimer's disease (AD) (McKenney 2003; Jick et al, 
2000; Vega et al, 2003). Despite growing evidence for beneficial effects of statins in 
various CNS diseases including stroke, AD and multiple sclerosis, there is yet no 
evidence that suggest any kind of relevance of statins to Parkinson's disease (PD).  
                  Parkinson’s disease is a progressive neurodegenerative disorder, and its 
principal pathological characteristic is the loss of dopaminergic neurons of the substantia 
nigra pars compacta subsequently resulting in progressive dopamine loss in the basal 
ganglia. When dopaminergic neuronal death exceeds a critical threshold: 50-60% of 
substantia nigra pars compacta and 70-80% of striatal nerve terminals, Parkinsonian 
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syndrome appears (Bernheimer et al, 1973). This dopamine deficiency is significantly 
correlated to the severity of the main symptoms of PD. Studies in the rats have shown 
that motor activities are affected by the lesion of dopamine mesencephalic neurons in the 
substantia nigra (Ungerstedt et al, 1974;  Ungerstedt  et al, 1971). It was evidenced by 
lengthening movement time observed in monkeys after 6-OHDA-induced lesion of 
dopaminergic neurons (Viallet et al, 1984). This motor movement deficit is particularly 
apparent when the dopaminergic nerve terminals were damaged after local 6-OHDA 
administration in the dorsolateral part of the striatum which was recognized as the 
“motor part” of the structure in rodents (Amalric et al, 1987; Amalric et al, 1995). 
                  In addition to the behavior dysfunction in PD, numerous studies have 
indicated that this dopaminergic dysfunction is closely correlated to the occurrence of 
cognitive deficits in PD.                    
                 The nigro-striatal and mesocorticolimbic dopaminergic systems play an 
important role in the cognitive function in PD, and a prominent cognitive deficit in PD is 
subcortical dementia with symptoms similar to those caused by frontal lobe damage 
(Tamaru 1997). This is consistent with known dopaminergic dysfunction in the 
frontostriatal functional loop involving the prefrontal cortex, a region strongly implicated 
to be involved in cognitive, behavioral and motivational functions (Kaasinen et al, 2000; 
Kaasinen et al, 2003). Hughes (1997) also indicated that the cognitive deficit in PD is 
likely to be associated with the dysfunction of fronto-striatal functional loop based on 
decreased dopamine input and dopaminergic damage in the mesolimbic or fronto-striatal 
system. DA receptor downregulation in the prefrontal cortex has been shown to produce 
severe impairments in working memory in monkeys (Castner et al, 2000). Thus, 
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dysfunctions of the dopaminergic systems in the prefrontal cortex in PD may underlie 
cognitive impairments in severe PD patients (Dubois et al, 1995; Rogers et al, 1998). 
Interestingly, the author has most recently reported that simvastatin treatment 
upregulates the expression of dopamine (D1 and D2) receptors in the rat prefrontal cortex 
(Wang et al, 2005). Therefore, the author has decided to investigate if simvastatin might 
reverse the downregulation of D1 and D2 receptors in the prefrontal cortex after 6-OHDA 
lesions of the medial forebrain bundle.  
 
               
          6.2. Methods 
                       6.2.1. Parkinson disease animal model—6-OHDA lesioned rats--set up  
                      Adult male Sprague-Dawley rats (weight 280g--300g) were 
anesthetized with chloral hydrate (400mg/kg, i.p.) and then mounted on a stereotaxic 
apparatus (Stoelting, Wood Dale, Illinois, USA) equipped with a carrier-mounted 
10μl Hamilton syringe. Lesions were made by injecting unilaterally 6-
hydroxydopamine (6-OHDA)(4μl of 8μg/μl in normal saline containing 0.2mg/ml 
ascorbic acid, Sigma, USA) into the medial forebrain bundle through the 10 μl 
Hamilton syringe at the following coordinates: Antero-posterior (AP): -4.4, L: -1.4 
and V: -7.8, incisor bar: -2.3mm from Bregma).(Holm et al, 2001). 6-OHDA was 
infused at rate of 0.8μl/min, and the needle was withdrawn 5 min after completion of 
injection. The control group was infused with 0.9% saline.  
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                 6.2.2. Circling behavior and simvastatin pre-treatment  
                      Locomotor activity was tested 4 weeks after unilateral 6-OHDA lesion. 
Circling behavior (rotations) for 10 min, starting 25 min after administering 
amphetamine (5mg/kg i.p.) (Holm et al 2001) following a 30-min period of 
habituation in a vertical Plexiglas cylinder (30-cm diameter) (Guillin et al 2001). Rats 
that showed significant ipsilateral rotational behavior (>7 rotations/min) were given 
daily simvastatin (10mg/kg) for 4 weeks by oral administration. The three groups 
were: control group,(sham-lesioned saline treated), 6-hydroxydopamine-lesioned 
saline treated group, and 6-hydroxydopamine-lesioned simvastatin treated  group.  
                        All RT-PCR and Western blot methods are described in chapter 2.  
  
 
              6.3. Results                            
                      Fig 6.1 and Fig 6.2 showed that expressions of D1 and D2 receptors in the 
prefrontal cortex were reduced by 74% and 80%, respectively, after 6-OHDA lesioning. 
However in the striatum, the author did not find any change for D1 and D2 receptors (Fig 
6.3 and Fig 6.4). Simvastatin treatment caused a 3.8-fold and 5.4-fold increase in D1 
receptor and D2 receptor mRNA respectively in the prefrontal cortex of 6-OHDA-
lesioned rats. In other words, simvastatin treatment restored dopamine receptor 
expression in the prefrontal cortex to the normal levels in control rats.  These results were 
confirmed at the protein level by Western blot analysis as shown in Fig 6.5 and 6.6.    
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                  6.4. Discussion 
                  Parkinson disease (PD) is neuropathologically characterized by a progressive 
loss of pigmented neurons with Lewy bodies in the substantia nigra. This progressive 
neuronal death of dopamine-producing cells leads to a lack of dopamine in the striatum.  
                 Unilateral injection of the neurotoxin 6-OHDA to lesion the nigrostriatal 
dopaminergic pathway in rats is a well-established Parkinsonian model (Ungerstedt, 
1986). With extensive unilateral destruction of the dopaminergic input into the striatum 
(Zhang et al., 1988), rats showed ipsilateral rotational movement when challenged with 
amphetamine (Siever et al, 1981). It is known that both D1 and D2 receptors are 
upregulated in the striatum after 6-OHDA lesions of the nigrostriatal pathway leading to 
receptor supersensitivity after denervation (Dawson et al, 1991; Narang et al, 1995).  In 
the present study, expression of both D1 and D2 receptors in the striatum of 6-OHDA 
lesioned rats were not observed to differ from controls at 8 weeks postlesion. Simvastatin 
treatment also had no effects on the striatal D1 and D2 receptor expressions (Fig. 6.3 and 
Fig 6.4). Consistently, upregulation of striatal D1 receptors was previously observed at 4 
weeks after lesion but returned to normal by 8 weeks. In contrast, striatal D2 upregulation 
persisted even at 8 weeks postlesion (Araki et al, 1998). This apparent difference in D2 
receptor expression at 8 week postlesion is most probably due to the fact that the 
expression of mRNA was measured presently while receptor binding was measured 
previously (Araki et al, 1998, Araki et al, 2000). It should also be noted that both D1 and 
D2 receptor bindings were unmodified in postmortem human caudate nucleus and 
putamen obtained from PD patients (Pimoule et al, 1985, Rinne et al, 1991).    
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                  More interestingly, it was observed that D1 and D2 receptor mRNA 
expressions were significantly reduced to 20–26% of control levels in the prefrontal 
cortex (Figure 6.1 Figure 6.2). These were further confirmed at the protein level where 
receptor expression was reduced to 48–53% of control levels (Figure 6.5 and Figure 6.6). 
The present author and coworkers have previously reported that simvastatin at 10 
mg/kg/day for 4 weeks maximally upregulated dopamine receptors in the prefrontal 
cortex of Sprague–Dawley rats leading to demonstrable increase in dopamine receptor 
functions (Wang et al., 2005). The same regimen of simvastatin treatment is presently 
shown to completely restore the expression of both D1 and D2 receptors to control levels 
in the 6-OHDA-lesioned rats, while it had no effects on the striatal D1 and D2 receptor 
expression.  
                 PD is caused by the degeneration of dopaminergic neurons in the nigrostriatal 
pathway leading to a loss of dopamine in the striatum. Upregulation of striatal D2 
receptors due to the loss of dopaminergic innervation has been demonstrated by positron 
emission tomography (PET) (Antonini et al, 1997; Rinne et al, 1990). In addition, 
increased D2 receptor density has been reported to occur in the putamen but not in the 
caudate nucleus in early PD (Rinne et al, 1995). To the contrary, D2 receptor decline has 
been observed in the dorsolateral prefrontal cortex as well as the anterior cingulate cortex 
and the thalamus in advanced PD (Kaasinen et al, 2000). This is consistent with the 
presently observed decrease in dopamine receptor expression in the prefrontal cortex of 
the 6-OHDA-lesioned rats. Information on the disposition of D1 receptors in the 
prefrontal cortex of the PD brain is lacking.  
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               Both the nigrostriatal and mesocorticolimbic dopaminergic systems have been 
shown to play a role in cognitive deficits in PD (Mattila et al, 2001; Mehta et al, 1999;  
Tamaru 1997), including memory disturbance, attention deficit, poor executive function 
(solving of emerging non-routine problems) and slowness in cognition. Moreover, 
performance in frontal lobe tasks in PD patients has been demonstrated to be improved 
by the D1/D2 agonist pergolide (Kulisevsky et al, 2000). Dihydrexidine, a selective D1 
agonist, could ameliorate deficits in spatial working memory in monkeys chronically 
treated with low dose MPTP (Schneider et al, 1994). All these support the idea that 
cognitive deficits are likely associated with dopaminergic dysfunction in the frontostriatal 
functional loop caused by decreased dopamine input early in PD (Hughes et al, 1997) as 
well as decline in dopamine receptors in advanced PD (Kaasinen et al, 2000; Kaasinen et 
al, 2003). Therefore, the present observation that simvastatin treatment reversed the 
downregulation of D1 and D2 receptors in the prefrontal cortex suggests that simvastatin 
may have an effect on cognitive deficits associated with the loss of dopaminergic 
receptor function in advanced PD. Further evidence may be obtainable by using a primate 
PD model which is more suitable for behavioral testing.  
                The present observation that simvastatin treatment reversed the downregulation 
of D1 and D2 receptors in the prefrontal cortex may suggest a potential in countering the 
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Figure 6.1.    Expression of D1 receptor mRNA in the prefrontal cortex of control rats, 
6-OHDA-lesioned rats, and 6-OHDA-lesioned rats treated with simvastatin (Sim). Band 
intensity is expressed as a ratio relative to the corresponding β-actin band. Error bars 
represent SEM, n=6. One-way ANOVA: F (2, 15) =82.479, P<0.001 for D1, *P<0.001 
against control and **P<0.001 against 6-OHDA by post hoc analysis with Bonferroni 
correction.  Top panel shows typical bands of β-actin and D1 receptor in the same order 
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Figure 6.2.  Expression of D2 receptor mRNA in the prefrontal cortex of control rats 
(C), 6-OHDA-lesioned rats, and 6-OHDA-lesioned rats treated with simvastatin (Sim). 
Band intensity is expressed as a ratio relative to the corresponding β-actin band. Error 
bars represent SEM, n=6. One-way ANOVA: F (2, 15) =387.704, P<0.001 for D2, 
*P<0.001 against control and **P<0.001 against 6-OHDA by post hoc analysis with 
Bonferroni correction.  Top panel shows typical bands of β-actin and D2 receptor in the 
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Figure  6.3.   Expression of D1 receptor mRNA in the striatum of control rats (C), 6-
OHDA-lesioned rats, and 6-OHDA-lesioned rats treated with simvastatin (Sim). Band 
intensity is expressed as a ratio relative to the corresponding β-actin band. Error bars 
represent SEM, n=6. One-way ANOVA: F (2,15)=0.102, P=0.904 for D1, P>0.9  against 
C and against 6-OHDA by post hoc analysis with Tukey correction. No statistical 
differences were obtained for the striatum.  Top panel shows typical bands of β-actin and 
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Figure  6.4.  Expression of D2 receptor mRNA in the striatum of control rats (C), 6-
OHDA-lesioned rats, and 6-OHDA-lesioned rats treated with simvastatin (Sim). Band 
intensity is expressed as a ratio relative to the corresponding β-actin band. Error bars 
represent SEM, n=6. One-way ANOVA: F (2,15)=0.455, P=0.643 for D2, P>0.6  against 
C and against 6-OHDA by post hoc analysis with Tukey correction. No statistical 
differences were obtained for the striatum.  Top panel shows typical bands of β-actin and 
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Figure 6.5.     Expression of D1 receptor protein in the prefrontal cortex of control rats, 
6-OHDA-lesioned rats, and 6-OHDA-lesioned rats treated with simvastatin (Sim). Band 
intensity is expressed as a ratio relative to the corresponding β-actin band. Error bars 
represent SEM, n=6. One-way ANOVA: F(2,15)=27.132, P<0.001 for D1. *P<0.001 
against control and **P<0.001 against 6-OHDA by post hoc analysis with Bonferroni 
correction.  Top panel shows typical bands of β-actin and D1 receptor in the same order 
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Figure 6.6.    Expression of D2 receptor protein in the prefrontal cortex of control rats, 
6-OHDA-lesioned rats, and 6-OHDA-lesioned rats treated with simvastatin (Sim). Band 
intensity is expressed as a ratio relative to the corresponding β-actin band. Error bars 
represent SEM, n=6. One-way ANOVA: F (2,15)=18.256, *P<0.002, **P<0.002 for D2. 
*P<0.002 against control and **P<0.002 against 6-OHDA by post hoc analysis with 
Bonferroni correction.  Top panel shows typical bands of β-actin and D1 receptor in the 



































 The work presented in this thesis showed that chronic treatment with simvastatin 
affected the central dopaminergic system in the rat prefrontal cortex. The dopamine-
mediated mesocorticolimbic pathways are linked to the brain reward and reinforcing 
circuits, and thus relevant to drug abuse and addiction (Bonci et al., 2003). Dopaminergic 
abnormality is also associated with the pathogenesis of schizophrenia (Harrison, 2000). 
Thus, it is reasonable to expect profound effects of simvastatin in the CNS. However, it is 
known that significant adverse events relating to the CNS has not been reported after 
long-term use of statins in humans (Pedersen et al., 1996). This can be explained by the 
fact that the simvastatin dose required to effect changes in the dopaminergic system in the 
prefrontal cortex (10 mg/kg/day or above) is much higher than the equivalent clinical 
doses that are used in patients (10 mg/day) for hypercholesterolemia.  
 On the other hand, current evidence indicates that statins are neuroprotective 
[Chen et al 2003, Endres et al 2004, Zacco et al 2003] against ischemia in rodents at 
doses comparable to that used in the present study, and the mechanism involves the 
upregulation of endothelial nitric oxide synthase (eNOS) [Endres et al 2004]. Statins may 
also act indirectly by decreasing factors such as oxidized low density lipids (LDL), 
oxidized LDL receptor 1 and rho, which negatively regulates eNOS expression [Laufs et 
al 2003]. Although the upregulation of dopamine receptors in the prefrontal cortex occurs 
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simultaneously with that of eNOS [Siever et al 1981], results from eNOS knock out mice 
and the use of dopamine receptor antagonists failed to indicate any causal relationship 
between the two changes. The mechanism that underlies the effect of simvastatin on 
dopaminergic functions remains to be elucidated. 
Both the nigrostriatal and mesocorticolimbic dopaminergic systems have been 
shown to play a role in cognitive deficits in PD [Mattila et al 2001, Mehta et al 1999, 
Tamaru 1997], and performance in frontal lobe tasks in PD patients could be improved 
by a dopamine agonist [Kulisevs.ky et al 2000]. Thus, cognitive deficits are likely 
associated with dopaminergic dysfunction in the frontostriatal functional loop caused by 
decreased dopamine input early in PD [Hughes 1997] as well as decline in dopamine 
receptors in advanced PD [Kaasinen et al 2000, 2003]. Therefore, the present observation 
that simvastatin treatment reversed the downregulation of D1 and D2 receptors in the 
prefrontal cortex suggests that simvastatin may have an effect on cognitive deficits 
associated with the loss of dopaminergic receptor function in advanced PD. Further 
evidence may be obtainable by using a primate PD model more suitable for behavioral 
testing. 
In conclusion, current evidence suggests that simvastatin and possibly other 
hydrophilic statins, may be used for neuroprotection in stroke patients and cognitive 
improvement in PD patients. However, the dosage required for such proposed therapeutic 
purposes are likely to be much higher than those that are currently used in the clinics. 
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